

**KENNEDY KRIEGER INSTITUTE,
INC. AND AFFILIATES**

**Reports on Federal Awards in Accordance with
Uniform Guidance**

June 30, 2020

Federal Entity Identification Number 52-1524965

Kennedy Krieger Institute, Inc. and Affiliates

Index

June 30, 2020

	Page(s)
Part I - Financial Statements and Schedule of Expenditures of Federal Awards	3
Report of Independent Auditors Consolidated Financial Statements.....	4-5
Consolidated Balance Sheets	6
Consolidated Statements of Operations and Changes in Net Assets	7-8
Consolidated Statements of Cash Flows.....	9
Notes to Consolidated Financial Statements	10-38
Report of Independent Auditors on Supplemental Consolidating Financial Statements.....	39
Supplemental Combining Financial Statements	40-43
Notes to Supplemental Consolidating Financial Statements.....	44
Schedule of Expenditures of Federal Awards.....	45-62
Notes to Schedule of Expenditures of Federal Awards	63-64
Part II - Reports on Compliance and Internal Control	65
Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	66-67
Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control Over Compliance in Accordance with the OMB Uniform Guidance	68-69
Part III – Schedule of Findings and Questioned Costs	70
Schedule of Findings and Questioned Costs.....	71-72
Summary Schedule of Prior Audit Findings.....	73-74

Part I
Financial Statements and
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2020



Report of Independent Auditors

To the Board of Directors of Kennedy Krieger Institute, Inc. and Affiliates

We have audited the accompanying consolidated financial statements of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute"), which comprise the consolidated balance sheets as of June 30, 2020 and 2019, and the related consolidated statements of operations and changes in net assets and of cash flows for the years then ended.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Kennedy Krieger Institute, Inc. and Affiliates as of June 30, 2020 and 2019, and the results of their operations, changes in net assets, and their cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matters


Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards for the year ended June 30, 2020 is presented for purposes of additional analysis as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and is not a required part of the consolidated financial statements. The information is the responsibility of management and was derived from and relates

directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated October 15, 2020 on our consideration of the Institute's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2020. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on the effectiveness of internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Institute's internal control over financial reporting and compliance.

A handwritten signature in cursive script that reads "PricewaterhouseCoopers LLP".

PricewaterhouseCoopers LLP
Baltimore, Maryland
October 15, 2020

Kennedy Krieger Institute, Inc. and Affiliates
Consolidated Balance Sheets
As of June 30, 2020 and 2019
(in thousands)

ASSETS	2020	2019
Current assets:		
Cash and cash equivalents	\$ 21,355	\$ 9,050
Patient receivables, less allowances of \$5,611 and \$5,016	31,304	24,742
Grant and contract receivable	4,395	4,825
Tuition receivable	4,923	4,201
Pledges receivable	1,412	2,656
Prepaid expenses and other	2,661	2,547
Total current assets	<u>66,050</u>	<u>48,021</u>
Non-current assets:		
Property and equipment, net	159,785	161,827
Investments:		
Board designated endowment	57,031	56,576
Investments limited as to use	8,363	8,261
Pledges receivable, less allowances of \$2,289 and \$2,234	704	1,701
Total non-current assets	<u>225,883</u>	<u>228,365</u>
Total assets	<u>\$ 291,933</u>	<u>\$ 276,386</u>
LIABILITIES AND NET ASSETS		
Current liabilities:		
Accounts payable and accrued expenses	39,074	35,743
Deferred grant revenue	4,797	1,738
Line of credit / short-term note	10,000	1,000
Current portion of tax-exempt bonds	3,292	3,204
Total current liabilities	<u>57,163</u>	<u>41,685</u>
Long-term liabilities:		
Tax-exempt bonds, net	73,986	77,247
Accrued pension	23,259	18,955
Interest rate swap	11,540	8,359
Other long-term liabilities	4,898	4,249
Total long-term liabilities	<u>113,683</u>	<u>108,810</u>
Total liabilities	<u>170,846</u>	<u>150,495</u>
Net assets:		
Without donor restrictions	93,588	101,591
With donor restrictions	27,499	24,300
Total net assets	<u>121,087</u>	<u>125,891</u>
Total liabilities and net assets	<u>\$ 291,933</u>	<u>\$ 276,386</u>

See accompanying notes to consolidated financial statements

Kennedy Krieger Institute, Inc. and Affiliates
Consolidated Statements of Operations and Changes in Net Assets
for the years ended June 30, 2020 and 2019
(in thousands)

	2020	2019
Operating revenues:		
Patient service revenue, net of contractual allowances	\$ 186,188	\$ 176,977
Bad debt expense	(4,914)	(3,630)
Net patient service revenue	<u>181,274</u>	<u>173,347</u>
Tuition revenue	46,775	47,753
Grant and contract revenue	39,304	35,010
Net assets released for operating activities	6,725	6,441
Investment earnings used for operating activities	2,184	2,040
Contributions without donor restrictions, net	1,416	1,551
Other operating revenues	<u>869</u>	<u>1,161</u>
Total operating revenues	<u>278,547</u>	<u>267,303</u>
Operating expenses:		
Salaries, wages and benefits	209,435	202,227
Supplies, purchased services, and other	50,162	49,474
Depreciation and amortization	11,983	9,965
Rent	3,053	2,572
Interest	<u>3,346</u>	<u>2,530</u>
Total operating expenses	<u>277,979</u>	<u>266,768</u>
Operating revenues over operating expenses	568	535
Non-operating activity:		
Investment return, net	592	1,079
Realized and unrealized gain (loss) on interest rate swap	(4,100)	(2,778)
Fundraising expenses related to contributions with donor restrictions	<u>(1,258)</u>	<u>(1,168)</u>
Net non-operating activities	<u>(4,766)</u>	<u>(2,867)</u>
Excess of revenue (under) expenses	<u>\$ (4,198)</u>	<u>\$ (2,332)</u>

Continued on next page

Kennedy Krieger Institute, Inc. and Affiliates
Consolidated Statements of Operations and Changed in Net Assets
As of June 30, 2020 and 2019
(in thousands)

	2020	2019
Net assets without donor restrictions:		
Excess of revenue (under) over expenses	(\$4,198)	(\$2,332)
Net assets released from restriction for property and equipment	1,042	10,340
Change in funded status of defined benefit plan	(4,847)	(6,200)
(Decrease) / Increase in net assets without donor restrictions	(\$8,003)	1,808
Net assets without donor restrictions, beginning of year	\$101,591	\$99,783
Net assets without donor restrictions, end of year	\$93,588	\$101,591
Net Assets with donor restrictions:		
Contributions with donor restrictions	10,966	5,257
Net assets released from restrictions for operations	(6,725)	(6,441)
Net assets released from restrictions for property and equipment	(1,042)	(10,340)
Increase / (Decrease) in net assets with donor restrictions	3,199	(11,524)
Net assets with donor restrictions, beginning of year	24,300	35,824
Net assets with donor restrictions, end of year	27,499	\$24,300
(Decrease) in total net assets	(4,804)	(9,716)
Total net assets, beginning of year	125,891	135,607
Total net assets, end of year	\$121,087	\$125,891

Kennedy Krieger Institute, Inc. and Affiliates
Consolidated Statements of Cash Flows
As of June 30, 2020 and 2019
(in thousands)

	2020	2019
Cash flows from operating activities:		
Change in net assets	\$ (4,804)	\$ (9,716)
Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:		
Net realized and unrealized (gains) on investments	(444)	(466)
Depreciation and amortization	11,983	9,965
Bad debt expense	4,914	3,630
Change in pension liability, net	4,304	4,215
Change in valuation of interest rate swap	3,181	2,039
Contributions restricted for long-term purposes	(10,970)	(6,399)
Changes in assets and liabilities:		
Patient receivables	(11,476)	(6,060)
Other receivables	1,949	10,560
Prepaid expenses	(114)	(363)
Accounts payable and accrued expenses	3,331	1,635
Deferred grant revenue	3,059	(472)
Other liabilities	1,662	892
Net cash provided by operating activities	<u>6,575</u>	<u>9,460</u>
Cash flows from investing activities:		
Purchase of property and equipment	(9,941)	(26,558)
Net sales of investments	(11)	(195)
Draws on construction funds	-	7,676
Other changes in assets limited to use	(102)	(496)
Net cash (used in) investing activities	<u>(10,054)</u>	<u>(19,573)</u>
Cash flows from financing activities:		
Payments on tax-exempt bonds	(3,173)	(3,077)
Proceeds from line of credit/short term loan	50,500	31,750
Payments on line of credit	(41,500)	(30,750)
Payments on capital lease obligation	(1,013)	(566)
Proceeds from contributions restricted for long-term purposes	10,970	6,399
Net cash provided by financing activities	<u>15,784</u>	<u>3,756</u>
Net increase (decrease) in cash and cash equivalents	12,305	(6,357)
Cash and cash equivalents, beginning of year	9,050	15,407
Cash and cash equivalents, end of year	<u>\$ 21,355</u>	<u>\$ 9,050</u>
Cash paid during the year for interest	<u>\$ 3,346</u>	<u>\$ 2,530</u>

See accompanying notes to consolidated financial statements

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statements
As of June 30, 2020 and 2019
(in thousands)

1. DESCRIPTION OF ORGANIZATION

Kennedy Krieger Institute, Inc. and Affiliates (the "Institute") is an internationally recognized organization dedicated to improving the lives of children, adolescents and young adults through comprehensive patient care, education and research. The Institute's primary operating activities include healthcare services, research, training, special education and fundraising.

The operations of the Institute are carried out through a number of legal corporate entities. The consolidated financial statements of the Institute reflect the accounts of the following separate legal corporate entities:

Kennedy Krieger Institute, Inc.
Kennedy Krieger Children's Hospital, Inc.
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Kennedy Krieger Education and Community Services, Inc.
Kennedy Krieger Associates, Inc.
PACT: Helping Children with Special Needs, Inc.
Kennedy Krieger Foundation, Inc.
Madison Street Properties, Inc.

Healthcare services are provided through Kennedy Krieger Children's Hospital, Inc. and include a forty-five bed inpatient unit admitting more than 350 patients yearly, over fifty specialty outpatient clinics generating in excess of 204,500 annual visits and the training of over 400 healthcare professionals each year. Net patient service revenue generated through Healthcare activities represents approximately 65.1% and 64.9% of the Institute's operating revenue in fiscal years 2020 and 2019, respectively.

Grant and contract revenue represents approximately 14.1% and 13.1% of the Institute's operating revenue in fiscal years 2020 and 2019, respectively. Approximately 67.0% and 61.1% of this revenue in fiscal years 2020 and 2019, respectively, comes from departments and agencies of the United States government. Major government sponsors included the National Institutes of Health, Center for Disease Control, Health Human Services, Health Resources and Services Administration and the Department of Education.

Special education services provided through Kennedy Krieger Education & Community Services, Inc. are conducted through non-public special education schools for students from kindergarten to grade eight, high school, specialized autism programs and partnership programs within public schools. Tuition and related contractual revenue generated through special education services represents approximately 16.8% and 17.9% of the Institute's operating revenue in fiscal years 2020 and 2019, respectively.

Kennedy Krieger Institute, Inc., Kennedy Krieger Children's Hospital, Inc., Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Kennedy Krieger Education and Community Services, Inc., Kennedy Krieger Associates, Inc., and PACT: Helping Children with Special Needs, Inc. are Maryland non-stock corporations organized for charitable, scientific and educational purposes and are tax-exempt under Section 501(c)(3) of the Internal Revenue Code. Kennedy Krieger Foundation, Inc. (the "Foundation"), is a Maryland stock corporation and is tax-exempt under Section 501(c)(3) of the Internal Revenue Code.

Kennedy Krieger Institute, Inc. and Affiliates

Notes to Consolidated Financial Statements

for the years ended June 30, 2020 and 2019

(in thousands)

Madison Street Properties, Inc. ("MSP") is a tax-exempt supporting organization under Section 509(a)(3) of the Internal Revenue Code and is wholly owned by the Foundation. All real and personal property and leasehold rights owned by the Institute are held by MSP, that in turn leases or subleases the property back to each member of the corporate family utilizing it and also provides property management services, including maintenance, security and housekeeping.

The Institute maintains an independent affiliation with The Johns Hopkins University. The formal relationship between the parties is set forth in an affiliation agreement whereby (i) the medical, scientific and other professional staff of the Institute receive primary and adjunct appointments in the appropriate Johns Hopkins University Schools or departments; and (ii) each Institution's independent corporate status is retained. Goods and services are purchased and sold by each organization through arms length transactions.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements of the Institute have been prepared on the accrual basis, which conforms to accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Institute after elimination of all significant intercompany accounts and transactions.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include investments in highly liquid instruments with original maturities of three months or less. These investments are carried at cost, which approximates market value.

Investments and Investment Income

Investments in equity securities with readily determinable fair values and all investments in debt securities are classified as trading and are recorded at fair value in the Consolidated Balance Sheets.

Investment income is included in the non-operating activity section of the Statement of Operations. Investment income includes interest and dividends, realized and unrealized gains (losses) on investments.

Allowance for Doubtful Accounts

An allowance for doubtful accounts is recorded for patient receivables which are anticipated to become uncollectible in future periods. Receivables deemed to be uncollectible have been written off.

Grant and Contract Revenue and Receivable

Grant and contract revenues are recorded through cost reimbursement arrangements when allowable costs are incurred, through service rates as services are provided or when contractual

Kennedy Krieger Institute, Inc. and Affiliates

Notes to Consolidated Financial Statements

for the years ended June 30, 2020 and 2019

(in thousands)

terms are satisfied. Grant and contract receivables are recorded when earned. A reserve for uncollectible accounts has been estimated and recorded against grant and contract receivables.

Tuition Revenue and Receivable

Tuition revenue is recognized when earned over the school term (July to June). Tuition receivables are recorded when earned. The Institute does not record an allowance as tuition is paid in full by the local education agencies of the State of Maryland at state approved tuition rates.

Pledges Receivable

Unconditional promises to give cash and other assets to the Institute are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the commitment is received in writing.

Pledges receivable from capital campaigns and other contributions, have been recorded net of an allowance for uncollectible pledges. The allowance for uncollectible pledges receivable is estimated based on the nature and source of each pledge including pledge payment history and the donor's likelihood of honoring the commitment. The allowance is applied to pledges greater than one year. Multi-year pledges are recorded at their estimated present value using a risk-free rate of return of 3.5% for 2020 and 2019.

Excess of Revenue over Expenses

The Statements of Operations include excess of revenues over (under) expenses, which is the Institute's performance indicator. Changes in net assets without donor restrictions, which are excluded from excess of revenues over expenses consistent with industry practice, include unrealized gains and losses on investments, certain pension related transactions and assets acquired using contributions which by donor restrictions were to be used for the purpose of acquiring such assets.

Investments Limited as to Use

Investments limited as to use primarily include assets held by trustees under bond indentures, self-insurance trust arrangements, deferred compensation plans and other donor restricted gift arrangements.

Property and Equipment

Property and equipment acquisitions are recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives:

Buildings and Improvements	30-40 years
Fixed Equipment	10-15 years
Computer Software	10-15 years
Furniture and Equipment	3-5 years

Equipment purchases under grants, where title to the equipment rests with the grantor, are recorded as expenditures of the grant and are not capitalized or depreciated.

Capital Leases

Capital leased assets are amortized over the shorter of their estimated useful lives or the lease term. Depreciation expense on capitalized leased assets is included in depreciation and amortization expenses in the Consolidated Statements of Operations.

Deferred Financing Costs

Costs incurred related to the issuance of bonds payable have been deferred and are being amortized over the life of the bonds using the effective interest method. In fiscal year 2017, the

Kennedy Krieger Institute, Inc. and Affiliates

Notes to Consolidated Financial Statements

for the years ended June 30, 2020 and 2019

(in thousands)

Institute adopted ASU 2015-03, "Simplifying Presentation of Debt Issuance Costs". These debt issuance costs are now presented as a deduction from the carrying value of the associated debt.

Accrued Expenses

Accrued expenses are operating expenses that have been incurred but which have not been paid as of the balance sheet date. These expenses are typically periodic and due within one year or less. They include expenses incurred for payroll, employee benefits, subcontracts, interest and other operating items.

Deferred Grant Revenue

Deferred grant revenue has been recorded to reflect the portion of cash received on awarded grants where the grantor restrictions for its use have not been satisfied. Typically, the donor restrictions are satisfied within a year, therefore, deferred grant revenue is classified as a current liability.

Net Assets

Net assets without donor restrictions include undesignated amounts as well as amounts designated by the Board for a specific purpose. Net assets with donor restrictions are held by the Institute and consist primarily of amounts contributed to the Institute by donors with purpose restrictions. The Institute also has net assets with donor restrictions that are perpetual in nature. Earnings on these assets are available for use as specified by the donors.

Estimated Professional and General Liability Costs

The provision for estimated professional and general liability claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

Derivatives

The use of derivatives by the Institute is generally limited to interest rate swaps. The Institute follows accounting guidance on derivative financial instruments that are based on whether the derivative instrument meets the criteria for designation as cash flow or fair value hedges. The criteria for designating a derivative as a hedge include the assessment of the instrument's effectiveness in risk reduction, matching of the derivative instrument to its underlying transaction, and the assessment of the probability that the underlying transaction will occur. The Institute's only derivative financial instrument is an interest rate swap agreement without hedge accounting designation.

The Institute recognizes its interest rate swap as a liability on the Consolidated Balance Sheet at fair value. The change in the value of this derivative is recorded as an unrealized gain or loss in the Consolidated Statements of Operations.

Pension Plans

The Institute follows current technical guidance for reporting and accounting for pension benefits provided to employees. This guidance requires recognition of the funded status of a defined benefit plan in the balance sheet as an asset or liability if the plan is over funded or underfunded, respectively. Changes in the funded status of a plan are required to be recognized in the year in which the changes occur through changes in Net assets without donor restrictions. The guidance also requires the measurement date of the plan's funded status to be the same as the company's fiscal year end.

Short-term investments

Short-term investments are carried at fair value and are comprised of instruments with an average duration of 1 to 3 years.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

Investments

The fair values for marketable equity, government, and fixed income securities included in long-term investments are based on quoted market prices.

Long-term Debt Obligations

Management estimates that the fair value of long-term debt is equal to its carrying value.

Reclassifications

Certain reclassifications have been made to conform with the current year financial statement presentation.

New Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09 "Revenue from Contracts with Customers". This standard implements a single framework for recognition of all revenue earned from customers. This framework ensures that entities appropriately reflect the consideration to which they expect to be entitled in exchange for goods and services by allocating transaction price to identified performance obligations and recognizing revenue as performance obligations are satisfied. Qualitative and quantitative disclosures are required to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The standard will be effective for the Institute as of July 1, 2020. The Institute is evaluating the impact this will have on the consolidated financial statements beginning in fiscal year 2021, including changes to information technology systems, processes, contracted terms and internal controls because of the new standard and its disclosure requirements.

In January 2016, the FASB issued ASU 2016-01, "Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities". ASU 2016-01 addresses accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. Non-public business entities will no longer be required to disclose the fair value of financial instruments carried at amortized cost. The amendments in ASU 2016-01 are effective for years beginning after December 15, 2018. The Institute adopted this standard in fiscal year 2020.

In February 2016, the FASB issued ASU 2016-02 "Leases". This standard requires lessees to recognize assets and liabilities for the rights and obligations created by leases with terms in excess of 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease will primarily depend on its classification as a finance or operating lease. The accounting by lessors remains largely unchanged. This standard is effective for fiscal years beginning after December 15, 2019. Kennedy Krieger Institute is evaluating the impact this will have on the consolidated financial statements beginning in fiscal year 2021.

In August 2016, the FASB issued ASU 2016-14 "Presentation of Financial Statements of Not-for-Profit Entities". The new guidance requires improved presentation and disclosures to help not-for-profits provide more relevant information about their resources to donors, grantor, creditors and other users. Kennedy Krieger Institute adopted this presentation in fiscal year 2019.

In March 2017, the FASB issued ASU 2017-07, "Compensation-Retirement Benefits (Topic 715), Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost." The new guidance requires employers to report the service cost component of net periodic pension cost in the same line item as other compensation costs arising from services rendered by the pertinent employees during the period. The Institute adopted this standard for fiscal year 2020.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

In June 2018, the FASB issued ASU 2018-08, “Not-for-Profit Entities (Topic 958), Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made”. The new standard applies to all entities that receive or make contributions. The guidance clarifies the definition of transactions accounted for as an exchange transaction subject to ASU 2014-09 or other applicable guidance, and transactions that should be accounted for as contributions (non-exchange) subject to the contribution accounting model. Further, the guidance provides criteria for evaluating whether contributions are unconditional or conditional. Conditional contributions must specify a barrier that the recipient must overcome and a right of return that releases the donor from its obligation if the barrier is not achieved, otherwise the contribution is unconditional. The update is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Institute adopted this standard for fiscal year 2020.

The London Interbank Offered Rate (“LIBOR”) is used to price all of the Institute’s variable rate debt. At the end of 2021, LIBOR is expected to cease publication and market participants around the world have undertaken reference rate reform initiatives to identify alternative reference rates. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (ASC 848), to provide some relief to the operational challenges likely to arise due to the change in reference rates. This standard is adoptable as of the beginning of reporting periods including March 12, 2020, but can be adopted in any subsequent reporting period prior to December 31, 2022. The Institute’s variable rate financing agreements were modified with each bank debt holder as of August 20, 2020 to address the process for how the LIBOR reference rate will be replaced in each variable rate debt agreement.

3. NET PATIENT SERVICE REVENUE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS

Net patient service revenues from inpatient and outpatient services are reported at estimated net realizable amounts from patients, third-party payors, and others for services rendered including estimates for contractual allowances with third-party payors and bad debts.

The Institute has agreements with third-party payors that provide for payments to the Institute at amounts different from its established rates. Net patient service revenue is comprised of the following:

	2020	2019
Gross Inpatient Revenue	\$ 63,937	\$ 61,271
Less: Contractual Allowances	(14,028)	(12,927)
Bad Debt Expense	(1,022)	(357)
Net Inpatient Revenue	<u>48,887</u>	<u>47,987</u>
Gross Outpatient Revenue	155,237	143,513
Less: Contractual Allowances	(18,958)	(14,880)
Bad Debt Expense	(3,892)	(3,273)
Net Outpatient Revenue	<u>132,387</u>	<u>125,360</u>
Net Patient Service Revenue	<u>\$ 181,274</u>	<u>\$ 173,347</u>

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

The percentage of patient service revenue generated by payor category for the fiscal years ended June 30, 2020 and 2019 is as follows:

	2020	2019
Medicaid	34%	33%
Blue Cross	32%	30%
Commerical	31%	33%
Self pay and other	1%	2%
Medicare	2%	2%
	<u>100%</u>	<u>100%</u>

The Allowance for Doubtful Accounts is based upon management's assessment of historical and expected net collections considering trends in healthcare coverage, economic conditions and payor mix. Management assesses the adequacy of the allowance periodically based upon historical collection and write off experience. After collection of amounts due from insurers, the Institute follows internal guidelines for placing certain past-due balances with collection agencies.

	2020	2019
Beginning Allowance for doubtful accounts	\$ 5,016	\$ 5,529
Plus: Bad debt expense	4,914	3,630
Less: Bad debt write-offs, net of recoveries	<u>(4,319)</u>	<u>(4,143)</u>
Ending Allowance for doubtful accounts	<u>\$ 5,611</u>	<u>\$ 5,016</u>

A summary of the payment arrangements with major third-party payors and patient financial assistance follows.

Maryland Medicaid

Since January 1, 2007 the Institute has been under a prospective payment system ("PPS") with Maryland Medicaid for both inpatient and outpatient services. Service-based per diem rates for inpatient services are annually adjusted by market basket update factors published by the Centers for Medicare and Medicaid Services ("CMS"). Outpatient services are reimbursed as a percentage of charges and subject to the lower of cost versus charges. Base year costs are trended forward annually using the CMS outpatient PPS market basket update factor and compared to actual charges. No retroactive settlement occurs under these arrangements.

Out of State Medicaid

The Institute has entered into payment agreements with many out-of-state Medicaid plans. The majority of these payment agreements reflect similar rates paid by Maryland Medicaid. No retroactive settlement occurs under these agreements.

Commercial Insurance

The Institute has also entered into payment agreements with commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis of payment to the Institute under these agreements includes prospectively determined rates per day or discharge,

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

discounts from established charges and prospectively determined daily rates. No retroactive settlement occurs under these agreements.

Medicare

Certain inpatient and outpatient services rendered to Medicare beneficiaries are subject to retrospective cost-based reimbursement. Medicare cost reports have been filed through 2018 and final settled through 2017. No significant settlement due to or from the Medicare Program has been estimated and as a result no receivable or payable has been recorded at June 30, 2020 or 2019.

Financial Assistance and Community Benefit

The Institute provides services without charge or at discounted charges to patients who meet certain criteria under its financial assistance policy. The criteria for financial assistance considers the patient or patient's family's ability to pay at time of service. The Institute uses the federal poverty guidelines to determine eligibility for free care or discounted care. In addition, the Institute's policy applies to patients who are medically indigent. The Institute also offers payment plan options to assist patients who experience a financial hardship paying their hospital and professional services bills, but who might not qualify for financial assistance. In January 2016, the Institute expanded its financial assistance policy along with developing a plain language summary of the policy that is distributed to patients at registration.

The cost for services and supplies furnished under the Institute's financial assistance policy aggregated approximately \$1,238 and \$1,133 in 2020 and 2019, respectively. The cost has been estimated based on a cost to charge ratio and applied to financial assistance charges.

In addition to patient financial assistance and payment plan options, the Institute provides various community benefits across the developmental disability populations within the State of Maryland. The foundation of its community benefits envisions that all persons with developmental disabilities ("DD") lead fully inclusive and meaningful lives. A community needs assessment was conducted and is periodically updated to understand the needs of the community served. Based on the needs assessment, the Institute promotes and hosts educational forums, provides respite care resources, acts as a resource finder, provides advocacy and legal services, promotes and arranges information exchange among patients, families and professionals, promotes workforces development, is a leader in healthcare training in DD, and conducts research, among other things.

4. TUITION REVENUE

Tuition revenue generated by school programs is summarized as follows:

	2020	2019
High school	\$ 14,600	\$ 15,370
Lower/middle school	14,339	14,252
Leap/Autism	7,532	7,377
Montgomery County	7,831	7,751
Partnership programs	1,718	2,302
PACT daycare	485	639
Other	270	62
	<u>\$ 46,775</u>	<u>\$ 47,753</u>

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

Over 570 students are enrolled in special education programs each year and come from fourteen Maryland counties, Washington, D.C. and other sources. The percentage of tuition revenue generated by jurisdiction is as follows:

	2020	2019
Prince George's County, MD	22.5%	26.0%
Other local education agencies	21.2%	18.9%
Baltimore County, MD	17.0%	16.0%
Anne Arundel County, MD	13.7%	14.6%
Montgomery County, MD	10.5%	9.6%
Washington, DC	7.5%	7.1%
Baltimore City, MD	6.0%	6.9%
Private	1.6%	0.9%
Total	<u>100.0%</u>	<u>100.0%</u>

5. GRANT AND CONTRACT REVENUE

Grant and contract revenue is generated through the following activities:

	2020	2019
Research	\$ 24,653	\$ 26,312
Community service	6,341	6,474
Training / Hospital	2,818	2,224
Provider Relief Funds (CARES Act)	5,492	-
	<u>\$ 39,304</u>	<u>\$ 35,010</u>

Research revenue includes all research initiatives funded through government and private sources. Community service revenue consists of services provided to individuals and families with special needs in a community-based setting and is funded through government programs. Training revenue represents government funding of training programs for professionals in the field of developmental disabilities.

Grant and contract revenue includes recoveries of facility and administrative costs, with certain limitations and exclusions. Certain revenues and costs in current and prior years are subject to audit and retroactive settlement. No reserve has been recorded for any potential settlements as amounts are not known or are considered immaterial.

6. CARES ACT FUNDING

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted. The CARES Act provided stimulus funding to assist the US economy with the financial impact caused by the COVID-19 pandemic.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

Provider Relief Funds

The CARES Act funded \$100.0 billion in appropriations for a Provider Relief Fund to be used by healthcare organizations for preventing, preparing for, and responding to the coronavirus by reimbursing for health care related expenses and lost revenue that are attributable to COVID-19.

The Institute received \$8,473 in payments under the Provider Relief Fund as of June 30, 2020 and recognized \$5,492 as Grant and contract revenue on the Consolidated Statements of Operations and Changes in Net Assets based on publicly available information and guidance issued by the Department of Health and Human Services (HHS) available at June 30, 2020. The Institute has recorded the remaining \$2,981 as Deferred grant revenue on the Consolidated Balance Sheets. The Institute received another \$5,058 in Provider Relief Funds in August 2020.

In September 2020, HHS issued new reporting requirements for Provider Relief Fund payments. The new requirements first require the Institute to identify healthcare related expenses attributable to COVID-19 that another source has not reimbursed. If those expenses do not exceed the funding received, the Institute will need to demonstrate that the remaining Provider Relief Fund payments were used for a negative change in calendar year 2020 patient care operating income compared to calendar year 2019. HHS is entitled to recoup amounts in excess of the negative change in patient care operating income reported net of healthcare related expenses. Due to these new reporting requirements, there is a possibility that amounts recorded as Grant and contract revenue or as Deferred grant revenue in 2020 may have to be repaid to HHS.

Federal Communications Commission (FCC) funding

In April 2020 the Institute was awarded a grant from the FCC in the amount of \$995 to fund expenditures incurred to grow telehealth capacity as a result of the COVID-19 pandemic. The Institute recorded \$423 of this funding as Grant and contract revenue in 2020. It is anticipated that the remaining \$572 of funding will be recognized as Grant and contract revenue in 2021. Funds are invoiced and paid as expended.

Medicare Accelerated and Advance Payments Program

Under the CARES Act, CMS temporarily expanded its current accelerated and advance payment program for Medicare providers. Under this program, qualified healthcare providers could receive advanced or accelerated payments from CMS. The Institute received \$1,184 in advanced payments under this program. These advanced payments were received in May 2020. Amounts received under the advance program are reflected in Accounts payable and accrued expense on the Consolidated Balance Sheets at June 30, 2020. These payments will start being recouped by CMS in September 2020 and are expected to be recouped within a year.

Employer Payroll Tax Deferral

In April 2020, the Institute began deferring payment on its share of payroll taxes owed, as allowed by the CARES Act. The Institute is able to defer half of its share of payroll taxes owed until December 31, 2021, with the remaining half due by December 31, 2022. As of June 30, 2020, the Institute deferred \$2,267 of payroll taxes. This amount is reflected in Accounts payable and accrued expense on the Consolidated Balance Sheets as of June 30, 2020.

7. CONTRIBUTIONS FROM FUNDRAISING ACTIVITIES

During 2020 and 2019, the Institute recognized contributions from fundraising activities as summarized below:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

	2020	2019
<u>Contributions</u>		
With donor restrictions	\$ 10,966	\$ 5,257
Without donor restrictions	<u>1,416</u>	<u>1,551</u>
Total Contributions	12,382	6,808
<u>Fundraising expenses</u>		
Without donor restrictions	1,725	1,707
With donor restrictions	<u>1,258</u>	<u>1,168</u>
Total Expenses	<u>\$ 2,983</u>	<u>\$ 2,875</u>

Contributions with donor restrictions are made up of annual giving and capital campaign contributions which are classified as net assets with donor restrictions on the Consolidated Balance Sheets. Contributions that are donor restricted to be held in perpetuity reflect gifts where the corpus cannot be utilized but where investment earnings are available for use. These contributions are also classified as net assets with donor restrictions on the Consolidated Balance Sheets. Contributions that reflect gifts with no donor restrictions are reported on the Consolidated Statements of Operations as contributions without donor restrictions, net.

Fundraising expenses are reported as operating expenses for those expenses related to contributions without donor restrictions and as non-operating activity for those expenses related to contributions with donor restrictions. Expenses related specifically to special events are netted with the revenue from those events.

8. INVESTMENTS AND INVESTMENT INCOME

Investments at June 30, 2020 and 2019 consist of the following:

	2020	2019
Long-term investments		
Fixed income mutual funds	\$ 15,160	\$ 17,211
Equity mutual funds	<u>41,871</u>	<u>39,365</u>
Total long-term investments	<u>57,031</u>	<u>56,576</u>
Investments limited as to use		
Money market funds	239	635
Fixed income mutual funds	2,033	1,908
Equity securities and funds	<u>6,091</u>	<u>5,718</u>
Total assets limited to use	<u>8,363</u>	<u>8,261</u>
Total Investments	<u>\$ 65,394</u>	<u>\$ 64,837</u>

Changes in Long-term investments for the years ended June 30, 2020 and 2019 are as follows:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

	2020	2019
Long-term investments, beginning of year	\$ 56,576	\$ 55,915
Investment return, net	2,639	2,701
Investment earnings appropriated for expenditure	<u>(2,184)</u>	<u>(2,040)</u>
Long-term investments, end of year	<u>\$ 57,031</u>	<u>\$ 56,576</u>

The Investment Committee of the Board of Directors ("Investment Committee") sets the investment policy for the long-term investments, including investment and spending guidelines. Investments of the long-term investments are based on the objective of achieving capital appreciation and investment income. Assets are invested in a manner that is intended to achieve an average annual real return in excess of inflation while assuming an acceptable level of investment risk. To monitor the effectiveness of the investment strategy of long-term investments, performance goals are established and monitored related to benchmark indices and returns earned by comparable funds.

To satisfy its long-term rate of return objectives of the long-term investments, the Institute employs a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current income (interest and dividends). The investment policy includes a target asset allocation that is well diversified among suitable asset classes and that is expected to generate, on average, the level of expected return necessary to meet the long-term investments' objectives while assuming a level of risk (volatility) consistent with achieving that return.

The asset allocation of the Long-term investments at June 30, 2020 and 2019 is summarized below. The Investment Committee regularly reviews the actual asset allocation against the target and periodically rebalances the investment, as appropriate.

	Target Allocation	Actual Allocation	
		2020	2019
Equities	70%	72%	70%
Fixed income	30%	28%	30%
Absolute return funds	-	-	-
	<u>100%</u>	<u>100%</u>	<u>100%</u>

The investment policy also provides for a long-term investment earnings withdrawal to be used in support of operating activities, as determined by Institute management and approved through the annual budget. The annual withdrawal is determined based on 4% of the three-year average market value of the portfolio. Withdrawals of \$2,112 and \$2,031 were made in 2020 and 2019, respectively to fund operating needs and have been reported as operating revenues.

Investments with a market value of \$1,435 and \$1,417 as of June 30, 2020 and 2019, respectively have been pledged as collateral under the Institute's self-funded unemployment insurance plan.

Investments Limited As To Use

Investments limited as to use at June 30, 2020 and 2019 are made up of the following:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

	2020	2019
Self insurance trust fund	4,689	4,486
Deferred compensation	2,010	2,104
Donor restricted fund	1,093	1,091
Planned gifts, net of reserve	276	285
Donor advised fund	295	295
Total investments limited as to use	<u>8,363</u>	<u>8,261</u>

Investment Income and Gains and Losses

Investment income and gains and losses are comprised of the following:

	2020	2019
Investment income		
Interest and dividend income	\$ 2,296	\$ 2,443
Realized gain on investments, net	194	467
Less: Investment earnings appropriated for operating activities	(2,184)	(2,040)
Net investment income	<u>\$ 306</u>	<u>\$ 870</u>
Net unrealized gain on investments	<u>\$ 285</u>	<u>\$ 209</u>

Liquidity and Availability

Financial assets at June 30, 2020 are made up of the following:

Cash and cash equivalents	\$ 21,355
Patient receivable, net	31,304
Grant and contract receivable	4,395
Tuition receivable	4,923
Pledges receivable	2,116
Prepaid expenses and other current assets	2,661
Investments limited as to use	8,363
Long-term investments	57,031
Total financial assets	<u>\$ 132,148</u>
Less amounts not available:	
Investments limited as to use	\$ 8,363
Pledges receivable, in excess of 1 year	704
Financial assets not available to be used within one year	<u>\$ 9,067</u>
Financial assets available to meet general expenditures within one year	<u>\$ 123,081</u>

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

As part of the Institute's liquidity management plan, cash in excess of daily requirements is invested in either money market funds, short-term investments or long-term investments. Investment decisions are based on anticipated liquidity needs, such that financial assets are available as general expenditures, liabilities, and other obligations come due. Additionally, the Institute maintains a line of credit, as discussed in Note 14.

9. FAIR VALUE MEASUREMENTS

FASB's guidance on the fair value option for financial assets and financial liabilities permits companies to choose to measure many financial assets and liabilities, and certain other items at fair value. This guidance requires a company to record unrealized gains and losses on items for which the fair value option has been elected in its performance indicator. The fair value option may be applied on an instrument by instrument basis. Once elected, the fair value option is irrevocable for that instrument. The fair value option can be applied only to entire instruments and not to portions thereof.

Kennedy Krieger Institute follows the guidance on fair value measurements, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, establishes a framework for measuring fair value, and expands disclosures about such fair value measurements. This guidance applies to other accounting pronouncements that require or permit fair value measurements and, accordingly, this guidance does not require any new fair value measurements.

This guidance discusses valuation techniques such as the market approach, cost approach and income approach. The guidance establishes a three-tier level hierarchy for fair value measurements based upon the transparency of inputs used to value an asset or liability as of the measurement date. The three-tier hierarchy prioritizes the inputs used in measuring fair value as follows:

- Level 1 – Observable inputs such as quoted market prices for identical assets or liabilities in active markets;
- Level 2 – Observable inputs for similar assets or liabilities in an active market, or other than quoted prices in an active market that are observable either directly or indirectly; and
- Level 3 – Unobservable inputs in which there is little or no market data that requires the reporting entity to develop its own assumptions.

The financial instrument's categorization within the hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Each of the financial instruments below has been valued utilizing the market approach.

The following tables present the fair value of investments and liabilities as of June 30, 2020 and June 30, 2019, by the valuation hierarchy defined above and also presents information on the liquidity aspects of each investment.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

Fair Value of Investments
as of June 30, 2020

	Level 1	Level 2	Level 3	Total Fair Value
Investments:				
Money market funds (1)	\$ 239	\$ -	\$ -	\$ 239
Fixed income mutual funds (2)	17,194	-	-	17,194
Equity securities and funds (3)	47,666	-	-	47,666
Privately held investments (4)	-	-	295	295
Total Investments	<u>\$ 65,099</u>	<u>\$ -</u>	<u>\$ 295</u>	<u>\$ 65,394</u>
Liabilities:				
Interest rate swap (5)	<u>\$ -</u>	<u>\$ 11,540</u>	<u>\$ -</u>	<u>\$ 11,540</u>
Total Liabilities	<u>\$ -</u>	<u>\$ 11,540</u>	<u>\$ -</u>	<u>\$ 11,540</u>

Fair Value of Investments
as of June 30, 2019

	Level 1	Level 2	Level 3	Total Fair Value
Investments:				
Money market funds (1)	\$ 635	\$ -	\$ -	\$ 635
Fixed income mutual funds (2)	19,119	-	-	19,119
Equity securities and funds (3)	44,788	-	-	44,788
Privately held investments (4)	-	-	295	295
Total Investments	<u>\$ 64,542</u>	<u>\$ -</u>	<u>\$ 295</u>	<u>\$ 64,837</u>
Liabilities:				
Interest rate swap (5)	<u>\$ -</u>	<u>\$ 8,359</u>	<u>\$ -</u>	<u>\$ 8,359</u>
Total Liabilities	<u>\$ -</u>	<u>\$ 8,359</u>	<u>\$ -</u>	<u>\$ 8,359</u>

- (1) Money market funds include investments in short-term debt securities, including U.S. Treasury bills and commercial paper with same day or next day liquidity.
- (2) Fixed income mutual funds include funds whose underlying investments include domestic and international corporate bonds, obligations issued or guaranteed by the U.S. government or its agencies, bankers acceptances, bank certificates of deposit, repurchase agreements, commercial paper, fixed income instruments denominated in currencies of emerging market countries and fixed income instruments represented by forwards or derivatives including options, future contracts and swap agreements. All funds offer next day liquidity. All funds are traded in active markets.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

- (3) Equity funds include investments in common stock mutual funds with next day liquidity.
- (4) Privately held investments include common stock of a privately held company. There is currently no market for the common stock.
- (5) The Institute has classified the valuation of its interest rate swap in Level 2 of the fair value hierarchy. For over-the-counter derivatives that trade in liquid markets, such as interest rate swaps, model inputs (i.e. contractual terms, market prices, yield curves, credit curves, and measures of volatility) can generally be verified, and model selection does not involve significant management judgment.

10. PROPERTY AND EQUIPMENT

A summary of property and equipment at June 30, 2020 and 2019 is as follows:

	2020	2019
Land	\$ 4,657	\$ 4,657
Building and improvements	216,842	213,359
Furniture & equipment	59,030	44,976
	<u>280,529</u>	<u>262,992</u>
Less: Accumulated depreciation	(120,744)	(108,818)
	<u>159,785</u>	<u>154,174</u>
Construction in progress	0	7,653
Property and equipment, net	<u>\$ 159,785</u>	<u>\$ 161,827</u>

Depreciation expense was \$11,952 and \$9,917 in 2020 and 2019, respectively.

Capital Lease Obligations

The Institute maintains lease agreements for computer equipment, software and the renovation of leased space. The Institute records these leases as capital leases and capitalized the property and equipment on the Consolidated Balance Sheets.

The future minimum lease payments required under the capital lease are as follows:

2021	\$ 792
2022	833
2023	675
2024	282
2025	<u>57</u>
Total future minimum lease payments	<u>\$ 2,639</u>

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

11. PLEDGES RECEIVABLE

Pledges receivable at June 30, 2020 and 2019 are summarized below:

	2020	2019
Pledges receivable:		
With donor restrictions	3,454	5,047
Without donor restrictions	951	1,544
	<u>4,405</u>	<u>6,591</u>
Less: Present value adjustment	(181)	(304)
Allowance for uncollectible pledges	<u>(2,108)</u>	<u>(1,930)</u>
Net pledges receivable	2,116	4,357
Less: Pledges due within one year	<u>(1,412)</u>	<u>(2,656)</u>
Pledges due in one to five years	<u>\$ 704</u>	<u>\$ 1,701</u>

The present value adjustments for 2020 and 2019 were made utilizing discount rates in effects at the time of the gift. The allowance for uncollectible pledges has been estimated based on management evaluation of each pledge's likelihood to be collected and using historical pledge write-off experience.

12. SIGNIFICANT CONCENTRATIONS OF CREDIT RISK

Financial instruments which potentially subject the Institute to concentrations of credit risk consist primarily of cash and cash equivalents, investments and patient accounts receivable.

The Institute typically maintains cash and cash equivalents in commercial banks. The short-term investments consist primarily of money market funds. The Federal Deposit Insurance Corporation insures funds up to \$250,000 per depositor.

The fair value of the Institute's investments are subject to various market fluctuations which include changes in the interest rate environment and general economic conditions.

The Institute records patient receivables due for services provided to patients and others. The majority of these patients either qualify for federal/state assistance programs or have insurance through commercial insurance companies or managed care organizations. The Institute maintains reserves for potential losses and such losses have been within management's expectations. The mix of patient receivables due from patients and third-party payors at June 30, 2020 and 2019 are as follows:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

	2020	2019
Medicaid	14.0%	13.4%
Medicaid managed care	25.7%	11.1%
Total Medicaid	<u>39.7%</u>	<u>24.5%</u>
Commercial Insurance	31.8%	42.6%
Blue Cross	19.9%	23.9%
Self-pay and other	7.7%	7.2%
Medicare	<u>0.9%</u>	<u>1.8%</u>
	<u>100.0%</u>	<u>100.0%</u>

13. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at June 30, 2020 and 2019 are made up of the following:

	2020	2019
Accounts payable and other accrued expenses	\$ 13,007	\$ 14,326
Payroll	10,631	8,918
Vacation	6,668	5,675
Workers' compensation, unemployment and health benefits	5,215	3,414
Self-insurance - general/professional liability	1,641	1,617
Research subcontracts	<u>1,912</u>	<u>1,793</u>
	<u>\$ 39,074</u>	<u>\$ 35,743</u>

14. DEBT

Tax-exempt Bonds

Tax-exempt bonds issued through Maryland Health and Higher Educational Facilities Authority ("MHHEFA") at June 30, 2020 and 2019 consisted of the following:

	2020	2019
MHHEFA Series 2011 Bonds	\$ 14,238	\$ 15,417
MHHEFA Series 2012 Bonds	-	400
MHHEFA Series 2013 Bonds	15,355	16,070
MHHEFA Series 2017A Bonds	22,383	22,734
MHHEFA Series 2017B Bonds	<u>25,853</u>	<u>26,413</u>
	77,829	81,034
Less: Current portion	(3,292)	(3,204)
Less: Unamortized deferred financing costs	<u>(551)</u>	<u>(583)</u>
	<u>\$ 73,986</u>	<u>\$ 77,247</u>

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

The Series 2011 Bonds are privately placed with Bank of America through a \$19,610 non-bank qualified term loan with a maturity date of June 1, 2021. The loan is being amortized through July 1, 2036. Terms of the loan agreement call for interest to be paid based on a percentage of 30-day LIBOR plus a credit spread. Principal payments are due in monthly installments on the first day of each month.

The 2011 Bonds were refunded on August 20, 2020 through the issuance of MHHEFA Series 2020 Bonds in the amount of \$14,300 and held by Fulton Bank. Terms of the Series 2020 Bonds call for 10-year bank commitment with amortization continuing through July 1, 2036. Principal and interest to be paid monthly with interest determined based on a percentage of 30-day LIBOR plus a credit spread and subject to a LIBOR floor.

The Series 2012 Bonds were privately placed in October 2012 with BB&T through a \$7,880 non-bank qualified term loan with a maturity date of July 1, 2019. Terms of the loan agreement called for a fixed interest rate of 2.76% with monthly principal and interest payments.

The Series 2013 Bonds issued through MHHEFA were privately placed with Bank of America through a \$16,730 non-bank qualified term loan with a maturity date of July 1, 2023. The loan is being amortized through July 1, 2033. Principal and interest are due in monthly installments on the first day of each month. Terms of the loan call for a fixed interest rate of 3.62%.

The Series 2017A Bonds issued through MHHEFA were privately placed in March 2017 with CapitalOne Municipal Funding through a \$23,000 non-bank qualified term loan with a maturity date of April 1, 2027. The loan is being amortized through March 1, 2042. Principal and interest payments are due in monthly installments on the first day of each month. Principal payments began on April 1, 2019. Terms of the loan agreement called for a fixed rate of interest of 3.21%. Due to the change in the maximum federal corporate tax rate, the loan agreement was amended in May 2018, for a fixed rate of interest of 3.79%.

The Series 2017B Bonds issued through MHHEFA were privately placed with BB&T through a \$27,510 non-bank qualified term loan with a maturity date of April 1, 2027. The loan is being amortized through March 1, 2037. Terms of the loan agreement call for interest to be paid based on a percentage of 30-day LIBOR plus a credit spread. Principal and interest payments are due in monthly installments on the first day of each month.

On August 20, 2020 the terms of 2017B Bonds were amended by Truist Bank (formerly BB&T) to extend the bank commitment date through August 2030 and to lower the credit spread and put a LIBOR floor in place. Principal and interest payments continue to be due in monthly installments.

The obligated group for the Series 2011, 2012, 2013 and 2017A, 2017B and 2020 Bonds (the "Bonds") include Kennedy Krieger Institute, Inc. and each of its affiliated entities. The Bonds were issued in parity and contain certain restrictions on the Institute's ability to incur additional indebtedness, restrict its use of facilities, maintain stipulated insurance coverage and maintain a rate structure sufficient to meet its total annual cash requirements. The Institute must maintain compliance with certain debt covenants contained in the bond indentures and loan agreements. At June 30, 2020 and 2019, the Institute was in compliance with all debt covenants in accordance with these agreements.

The aggregate future maturities of bonds payable for the next five years and thereafter are summarized below at June 30, 2020.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

2021	\$ 3,292
2022	3,384
2023	3,471
2024	3,550
2025	3,642
Thereafter	60,490
	<u>\$ 77,829</u>

Unamortized deferred bond financing costs of \$551 in 2020 and \$583 in 2019 are netted against tax-exempt bonds. Amortization expense was \$30 and \$48 in 2020 and 2019, respectively.

Short-term note payable

On October 16, 2019 the Institute closed on a \$10,000 364-day, unsecured term note with Truist Bank (formerly BB&T). Proceeds from the short-term note payable was used for fund various operating, capital and working capital requirements associated with its electric health record system implementation. Pricing on the note payable was based on 30-day LIBOR plus a credit spread. The balance outstanding on the short-term note payable was \$0 at June 30, 2019 and \$10,000 at June 30, 2020.

Effective August 20, 2020, the short-term note was refunding by Truist Bank in the amount of \$10,250. The bank commitment extends to July 2025 on the taxable long-term note with loan amortization over 10 years. Interest on the long-term term note is based on 30-day LIBOR plus a credit spread and subject to a LIBOR floor. Principal payments are due in monthly installments on the first day of each month. It is secured as parity debt under all other indebtedness.

The aggregate future maturities of long-term notes payable for the next five years and thereafter are summarized below.

2021	\$ 103
2022	340
2023	811
2024	1,059
2025	1,143
Thereafter	6,794
	<u>\$ 10,250</u>

Lines of Credit

The Institute maintains working capital lines of credit with bank commitments under the lines of credit as follows:

Prior to July 1, 2019	\$ 10,000
July 1, 2019	20,000
April 1, 2020	17,000
July 1, 2020	15,000
August 20, 2020 and thereafter	15,000

Prior to August 20, 2020 the line of credit was unsecured and priced at 30-day LIBOR plus a credit spread through Bank of America. Effective August 20, 2020 the line of credit was moved to Truist Bank and secured as parity debt under existing loan agreements and priced at 30-day LIBOR plus a credit spread and subject to a LIBOR floor. The commitment on the line of credit extends for one

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

year. The balance drawn against the lines of credit were \$1,000 at June 30, 2019 and \$0 at June 30, 2020.

15. RETIREMENT PLANS

The Institute maintains defined benefit and defined contribution plans covering substantially all of its employees.

Defined Benefit Plan

The Institute's defined benefit pension plan (the "plan") provides benefits to staff-level employees based on years of service and the employees' final average compensation. The Institute's policy is to annually fund the amount necessary to meet minimum funding requirement under ERISA. Contributions of \$2,570 and \$2,756 were made for 2020 and 2019, respectively. The plan was amended effective April 1, 2019 to allow lump sum payments to employees hired before July 1, 1989 and to allow in-service distributions to Plan participants who reach normal retirement age while still employed. The settlement amount for these lump sum payments was \$4,947.

The net periodic benefit cost calculated in accordance with current guidance for employer's accounting for pension obligations is \$2,573 and \$3,845 for 2020 and 2019, respectively. The service cost components of net periodic pension cost is reported within salaries, wages and benefits on the Consolidated Statements of Operations and Changes in Net Assets.

The following table sets for the plan's funded status and benefit obligations recognized in the Institute's consolidated financial statements at June 30, 2020 and 2019:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

	2020	2019
<u>Change in benefit obligation:</u>		
Projected benefit obligation at beginning of year	\$ 58,761	\$ 54,872
Service cost	974	771
Interest cost	2,057	2,335
Actuarial loss (gain)	8,081	6,512
Benefits paid	(3,847)	(782)
Settlements paid	-	(4,947)
Projected benefit obligation at end of year	<u>\$ 66,026</u>	<u>\$ 58,761</u>
<u>Change in plan assets:</u>		
Fair value of plan assets at beginning of year	\$ 39,806	\$ 40,132
Actual return on plan assets	4,238	2,647
Employer contribution	2,570	2,756
Benefits paid	(3,847)	(782)
Settlements paid	-	(4,947)
Fair value of plan assets at end of year	<u>\$ 42,767</u>	<u>\$ 39,806</u>
Funded status at end of year	<u>\$ (23,259)</u>	<u>\$ (18,995)</u>
Recognized in noncurrent liabilities		
<u>Amounts not yet recognized in net periodic benefit cost and included in unrestricted net assets:</u>		
Accumulated actuarial gain (loss)	\$ (23,259)	\$ (20,063)
Net unrestricted net assets previously reflected	-	1,108
Net amount recognized	<u>\$ (23,259)</u>	<u>\$ (18,955)</u>
<u>Components of net periodic pension cost:</u>		
Service cost	\$ 974	\$ 771
Interest cost	2,057	2,335
Expected return on plan assets	(2,433)	(2,383)
Loss on amortization	1,975	1,431
Effect of settlement	-	1,691
Net periodic pension cost	<u>\$ 2,573</u>	<u>\$ 3,845</u>
<u>Changes in net assets not yet reflected in the statement of operations:</u>		
Unrecognized net loss (gain)	\$ 6,236	\$ 6,288
Amortization of unrecognized net loss	(1,975)	(3,122)
Total changes in plan assets and obligations not yet reflected	<u>\$ 4,261</u>	<u>\$ 3,166</u>
Total changes in plan assets and benefit obligations	<u>\$ 6,834</u>	<u>\$ 7,011</u>
Unrecognized net loss to be amortized over next fiscal year	<u>\$ (2,368)</u>	<u>\$ (1,975)</u>

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

	2020	2019
Additional information:		
Accumulated benefit obligation	\$ 65,986	\$ 58,761
Expected contributions in the following year	<u>\$ 3,500</u>	<u>\$ 3,315</u>

Expected benefit payments for fiscal year ending June 30, 2020:

2021	\$ 1,977
2022	2,141
2023	2,230
2024	2,291
2025	2,367
Next five years	13,523

**Weighted-average assumptions
to determine benefit obligations:**

	2020	2019
Discount rate	2.76%	3.55%
Salary increase	Non applicable	Non applicable
Measurement date	June 30	June 30

**Weighted-average assumptions
to determine pension expense:**

	2020	2019
Discount rates	3.55%	4.33%
Expected return on plan assets	6.00%	6.00%
Salary increase	Non applicable	Non applicable

The discounted rate assumption for fiscal years ending 2020 and 2019 was based on the FTSE Pension Above-Median Discount Curve as of June 30, 2020 and 2019. The mortality tables used in fiscal year 2020 are based on the RP-2014 mortality table, no collar adjustment, and the MP-2018 mortality projection scale.

In determining the expected long-term rate of return on plan assets, the Institute evaluated the historical long-term rate of return for each class of asset in determining an acceptable overall range of expected returns for the plan.

The following tables present fair value measurements for plan assets as of June 30, 2020 and 2019 by the valuation hierarchy as defined in footnote 8 and also includes the liquidity aspects of each investment:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

Fair Value of Investments
as of June 30, 2020

	Level 1	Level 2	Level 3	Total Fair Value
Investments:				
Money market funds (1)	\$ 221	\$ -	\$ -	\$ 221
Fixed income mutual funds (2)	13,965	-	-	\$ 13,965
Equity securities and funds (3)	28,581	-	-	28,581
Total Investments	<u>\$ 42,767</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 42,767</u>

Fair Value of Investments
as of June 30, 2019

	Level 1	Level 2	Level 3	Total Fair Value
Investments:				
Money market funds (1)	\$ 191	\$ -	\$ -	\$ 191
Fixed income mutual funds (2)	13,838	-	-	\$ 13,838
Equity securities and funds (3)	25,777	-	-	25,777
Total Investments	<u>\$ 39,806</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 39,806</u>

- (1) Money market funds include investments in short-term debt securities, including US Treasury bills and commercial paper with same day or next day liquidity.
- (2) Fixed income mutual funds include funds whose underlying investments include domestic and international corporate bonds, obligations issued or guaranteed by the U.S. government or its agencies, bankers acceptances, bank certificates of deposit, repurchase agreements, commercial paper, fixed income instruments denominated in currencies of emerging market countries and fixed income instruments represented by forwards or derivatives including options, future contracts and swap agreements. All funds offer next day liquidity. All funds are traded in active markets.
- (3) Equity funds include investments in common stock mutual funds with next day or monthly liquidity.

The plan's target allocations and actual asset allocation at June 30, by asset category, was as follows:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

	Target Allocation	Actual Allocation	
		2020	2019
Money market funds	-	0.5%	0.5%
Equities	65%	66.8%	64.7%
Fixed income	35%	32.7%	34.8%
Alternative investments	-	-	-
	<u>100%</u>	<u>100%</u>	<u>100%</u>

The objectives of the plan's investment strategy are to maximize the plan's funded status and minimize the Institute's contributions and plan expense.

The Investment Committee establishes a target asset allocation and regularly reviews the actual asset allocation against the target. It also periodically rebalances the investment allocations, as appropriate.

Defined Contribution Plan

The Institute maintains a qualified defined contribution retirement plan which is in compliance with section 401(k) of the Internal Revenue Code (IRC). The 401(k) plan is active and available to all employees (including all faculty and senior staff members) and provides for up to a 50% employer match on employee contributions up to certain levels of compensation. During 2020 and 2019, the aggregate contributions to the 401(k) plan were \$20,942 and \$20,085.

Deferred Compensation Plan

The Institute also offers a non-qualified deferred compensation plan (457(b) of the IRC) for certain of its executives which allows for the deferral of compensation up to IRS limits. A deferred compensation balance of \$2,010 and \$2,104 in fiscal years 2020 and 2019, respectively, was reported in Investments limited as to use in the Consolidated Balance Sheet. An associated liability of an equal amount is included in Other long-term liabilities in the Consolidated Balance Sheet. The Institute makes no contributions to the Deferred Compensation Plan.

16. INTEREST RATE SWAP

The Institute manages the fixed/variable mix of its debt portfolio, including hedging exposure to increasing interest expense on variable rate debt, by utilizing an interest rate swap. The Institute maintains a fixed payor interest rate swap which hedges the variable interest rate risk on the majority of the outstanding balance of the Series 2017B and 2011 Series Bonds. Under the terms of the agreement with a local bank, the Institute pays a fixed rate of 3.636% and receives 67% of 30-day LIBOR on notional amounts that reduce annually until July 2036. Notional amounts of \$35,239 and \$36,064 were effective June 30, 2020 and 2019, respectively. Under the terms of the agreement, no collateral requirements exist on the part of the Institute.

The fair value of the interest rate swap and the related unrealized (losses) were as follows as of June 30, including the classification on the Consolidated Balance Sheets and Statements of Operations:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

	Fair Market Value	
	2020	2019
Interest rate swap liability	<u>\$ 11,540</u>	<u>\$ 8,359</u>
	Amount recognized in Non-operating activity	
	2020	2019
Unrealized loss on interest rate swap valuation	\$ (3,181)	\$ (2,039)
Interest rate swap payments	<u>(919)</u>	<u>(739)</u>
Total	<u>\$ (4,100)</u>	<u>\$ (2,778)</u>

17. NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions were held for the following purposes at June 30, 2020 and 2019:

	2020	2019
Capital Campaigns	\$ 2,168	\$ 3,989
Research and clinical projects	22,917	19,082
Perpetual in nature	<u>2,414</u>	<u>1,229</u>
	<u>\$ 27,499</u>	<u>\$ 24,300</u>

During 2020 and 2019, net assets with donor restrictions were released by satisfying donor restrictions in the following amounts:

	2020	2019
Property and equipment	\$ 1,042	\$ 10,340
Operating activities	<u>6,725</u>	<u>6,441</u>
Total	<u>\$ 7,767</u>	<u>\$ 16,781</u>

18. SELF INSURANCE

Professional and General Liability

The Institute maintains a self-insurance trust (the "Trust") for general and professional liability to cover liability claims arising out of the ordinary course of its business. Excess coverage with an insurance company is in place to cover losses above self-insured retention levels.

Assets in the Trust are to provide for payment of professional and general liability claims and expenses. Potential losses from asserted and unasserted claims are accrued based on estimates that incorporate the Institute's past experience, as well as other considerations, including the nature of each claim or incident, applicable insurance coverage and relevant trend factors.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

An accrued liability related to asserted and unasserted self-insured general and professional liability claims of \$1,641 and \$1,617 has been recorded at June 30, 2020 and 2019, respectively, and is included in Accounts payable and accrued expenses on the Consolidated Balance Sheets. Investments in the Trust have a market value of \$4,689 and \$4,486 at June 30, 2020 and 2019, respectively and are reported in Investments limited as to use on the Consolidated Balance Sheets.

Workers' Compensation, Unemployment and Health Benefits

The Institute self-insures its workers' compensation, unemployment and employee health and dental benefits. Losses from claims identified by the Institute, as well as provisions for estimated losses for incurred but not reported incidents, are accrued based on estimates that incorporate the past experience of the Institute, as well as other considerations, including the nature of the claims or incidents and relevant trend factors. An accrued liability of \$5,215 and \$3,414 has been recorded at June 30, 2020 and 2019, respectively for these self-insured plans and is included in Accounts payable and accrued expenses on the Consolidated Balance Sheets.

19. COMMITMENTS AND CONTINGENCIES

Litigation

The Institute is involved in claims and litigation on professional liability and personnel matters that arise in the ordinary course of its business. This litigation is not expected to result in losses that exceed insurance limits or have a materially adverse effect on the Institute's financial position.

There have been claims filed against the Hugo W. Moser Research Institute at Kennedy Krieger, Inc. arising out of two Federally-funded research studies performed in the early 1990s. The Institute has insurance believed adequate to cover any compensatory damages awarded for these claims. The Institute has been successful in defending its position on these cases and do not anticipate any material exposure going forward.

Rental Lease Commitments

Through the creation of MSP, all property and major equipment is leased/subleased to each operating entity. These transactions are eliminated through the consolidating of the Institute's financial statements.

Commitments for leases that do not meet the criteria for capitalization are classified as operating leases with related rentals charged to operations as incurred. The following is a schedule by year of future minimum lease payments under operating leases as of June 30, 2020, that have initial or remaining lease terms in excess of one year.

2021	\$ 3,088
2022	2,271
2023	1,539
2024	730
2025	442
Thereafter	2,238
	<u>\$ 10,308</u>

Rent expense on external lease commitments for the years ended June 30, 2020 and 2019 was \$3,053 and \$2,572 respectively.

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

Charitable Gift Annuities

The Institute has received charitable gift annuities from donors from which the Institute has guaranteed payments to the donor on a quarterly basis until the donor's death.

The Institute has recorded gift annuities, net of reserves, consistent with the rates adopted by the American Council on Gift Annuities at the time of issuance of the gift annuity. Assets maintained on outstanding annuity agreements exceed the amount of the reserve. Gift annuities with a market value of \$763 and \$707 and reserves for annuity payments of \$487 and \$422 to make gift annuity payments have been recorded in 2020 and 2019, respectively, and are included in Investments limited as to use on the Consolidated Balance Sheets.

Epic Outpatient Clinical System

The Institute entered into agreements with Epic to license and implement a new clinical system for use in outpatient services. As part of the agreements, the Institute committed to a 4-year payment plan which included both the license fees and implementation costs. Through the end of fiscal year 2020, \$4,396 has been paid under this commitment. The future year commitments are as follows:

2021	1,561
2022	1,041
	<u>\$ 2,602</u>

20. FUNCTIONAL EXPENSES

The Institute provides specialty pediatric health care services, conducts laboratory and clinical research, operates special education school programs and administers community-based services, conducts fundraising activities and provides institutional support. Costs not directly attributable to a function, including depreciation and interest, are allocated to function based on square footage. Expenses related to providing these services are as follows:

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Consolidated Financial Statement
for the years ended June 30, 2020 and 2019
(in thousands)

June 30, 2020

	Healthcare	Research	Education/ Community Svcs	Fundraising	Institutional Support	Total
Salaries, wages and benefits	\$129,854	\$18,370	\$38,210	\$2,144	\$21,978	\$210,556
Supplies and other	18,101	7,701	3,991	990	20,160	\$50,943
Rent	2,545	-	508	-	-	\$3,053
Interest	1,558	343	956	16	473	\$3,346
Depreciation	5,581	1,227	3,421	59	1,695	\$11,983
Total	\$157,639	\$27,641	\$47,086	\$3,209	\$44,306	\$279,881

June 30, 2019

	Healthcare	Research	Education/ Community Svcs	Fundraising	Institutional Support	Total
Salaries, wages and benefits	\$122,028	\$14,888	\$39,309	\$2,064	\$25,113	\$203,402
Supplies and other	19,523	9,593	4,238	1,495	15,302	\$50,151
Rent	1,888	-	452	-	232	\$2,572
Interest	1,196	243	696	12	383	\$2,530
Depreciation	4,712	956	2,740	50	1,507	\$9,965
Total	\$149,347	\$25,680	\$47,435	\$3,621	\$42,537	\$268,620

21. SUBSEQUENT EVENTS

The Institute has evaluated subsequent events through October 15, 2020, which is the date the Consolidated Financial Statements were issued. There have been no events subsequent to that date that needed to be disclosed.



Report of Independent Auditors

To the Board of Directors of Kennedy Krieger Institute, Inc. and Affiliates,

We have audited the consolidated financial statements of Kennedy Krieger Institute, Inc. and Affiliates as of and for the year ended June 30, 2020 and our report thereon appears on page 1 of this document. That audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The consolidating information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the consolidating information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position, results of operations and cash flows of the individual companies and is not a required part of the consolidated financial statements. Accordingly, we do not express an opinion on the financial position, results of operations and cash flows of the individual companies.

PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP
Baltimore, MD
October 15, 2020

SUPPLEMENTAL CONSOLIDATING FINANCIAL STATEMENTS

Kennedy Krieger Institute, Inc. and Affiliates
Consolidating Balance Sheet Information
Year Ended June 30, 2020

	Kennedy Krieger Children's Hospital, Inc.	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Kennedy Krieger Education & Community Services, Inc.	Kennedy Krieger Foundation, Inc.	PACT: Helping Children with Special Needs, Inc.	Madison Street Properties, Inc.	Consolidating Eliminations	Consolidated Totals
Assets								
Current assets:								
Cash and cash equivalents	\$ 7,598,922			\$ 13,240,204	\$ 515,953			\$ 21,355,079
Patient receivables, net	27,952,500		\$ 3,241,524		109,501			31,303,525
Grant and contract receivable	707,840	\$ 2,597,844	737,175		352,614			4,395,473
Tuition receivable			4,922,605					4,922,605
Pledges receivable				1,392,498	19,500			1,411,998
Due from affiliates	64,950,500		4,970,643		263,088		\$ (70,184,231)	
Prepaid expenses and other	2,196,913	269,055	268,761	1,667	1,697	\$ 107,751	(185,000)	2,660,844
Total current assets	103,406,675	2,866,899	14,140,708	14,634,369	1,262,353	107,751	(70,369,231)	66,049,524
Non-current assets:								
Property and equipment, net						159,785,430		159,785,430
Board designated endow ment				56,641,600	389,888			57,031,488
Investments limited as to use	6,698,776			1,664,001				8,362,777
Pledges receivable, net				703,982				703,982
Total non-current assets	6,698,776	-	-	59,009,583	389,888	159,785,430	-	225,883,677
Total assets	\$ 110,105,451	\$ 2,866,899	\$ 14,140,708	\$ 73,643,952	\$ 1,652,241	\$ 159,893,181	\$ (70,369,231)	\$ 291,933,201
Liabilities and net assets								
Current liabilities:								
Accounts payable and accrued expenses	\$ 34,458,840	\$ 2,035,490	\$ 204,936	\$ 45,080	\$ 31,691	\$ 2,298,727		\$ 39,074,764
Deferred grant revenue	3,000,018	1,460,031	231,505		105,352			4,796,906
Due to affiliates		8,051,237		5,811,962		56,321,032	(70,184,231)	-
Line of credit / short term note								-
Current portion of long-term liabilities	10,000,000					3,291,519		13,291,519
Total Current Liabilities	47,458,858	11,546,758	436,441	5,857,042	137,043	61,911,278	(70,184,231)	57,163,189
Non-current Liabilities:								
Tax-exempt bonds, net						73,986,501		73,986,501
Accrued pension	23,259,080							23,259,080
Interest rate sw ap						11,539,990		11,539,990
Other long-term liabilities	3,856,906					1,040,916		4,897,822
Total long-term liabilities	27,115,986	-	-	-	-	86,567,407	-	113,683,393
Total liabilities	74,574,844	11,546,758	436,441	5,857,042	137,043	148,478,685	(70,184,231)	170,846,582
Net assets:								
Without donor restrictions	32,404,708	(19,600,603)	12,761,217	56,372,215	420,928	11,414,496	(185,000)	93,587,961
With donor restrictions	3,125,899	10,920,744	943,050	11,414,695	1,094,270			27,498,658
Total net assets	35,530,607	(8,679,859)	13,704,267	67,786,910	1,515,198	11,414,496	(185,000)	121,086,619
Total liabilities and net assets	\$ 110,105,451	\$ 2,866,899	\$ 14,140,708	\$ 73,643,952	\$ 1,652,241	\$ 159,893,181	\$ (70,369,231)	\$ 291,933,201

Kennedy Krieger Institute, Inc. and Affiliates
Combining Statement of Operations
Year Ended June 30, 2020

	Kennedy Krieger Children's Hospital, Inc	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Kennedy Krieger Education & Community Services, Inc.	Kennedy Krieger Foundation Inc.	PACT: Helping Children with Special Needs, Inc.	Madison Street Properties Inc.	Consolidating Eliminations	Consolidated Totals
Operating revenues:								
Patient service revenue, net	\$ 176,385,761	\$ 2,651,762	\$ 2,074,694		\$ 162,118			\$ 181,274,335
Tuition revenue			46,290,110		484,881			46,774,991
Grants and contract revenue	8,309,778	24,653,419	4,648,902		1,691,661			39,303,760
Net assets released for operating activities	1,049,351	2,225,641	1,208,463	\$ 3,205,342	78,224		\$ (1,041,569)	6,725,452
Investment earnings used for operating activities		2,183,663						2,183,663
Contributions without donor restrictions, net				1,416,449				1,416,449
Other operating revenues	506,367	1,144,410	65,500		360,561	\$ 37,687,771	(38,895,781)	868,828
Total operating revenues	186,251,257	32,858,895	54,287,669	4,621,791	2,777,445	37,687,771	(39,937,350)	278,547,478
Operating expenses:								
Salaries, wages and benefits	136,814,074	19,793,338	41,279,461	1,099,592	2,372,221	8,075,834		209,434,520
Supplies, purchased services and other	23,980,925	9,579,711	6,315,127	3,312,811	312,597	11,161,424	(4,499,407)	50,163,188
Space costs, net	21,559,767	6,143,535	6,894,891	248,318	97,484	493,948	(35,437,943)	-
Depreciation						11,982,605		11,982,605
Rent						3,052,813		3,052,813
Interest	274,072	57,599	81,980	6,996	4,135	2,921,147		3,345,929
Total operating expenses	182,628,838	35,574,183	54,571,459	4,667,717	2,786,437	37,687,771	(39,937,350)	277,979,055
Operating revenues over (under) expenses	3,622,419	(2,715,288)	(283,790)	(45,926)	(8,992)	-	-	568,423
Non-operating activity:								
Investment return, net	301,083			278,604	11,493	904		592,084
Gain (loss) on interest rate swap						(4,100,664)		(4,100,664)
Fundraising expenses related to contributions with donor restrictions				(1,257,612)				(1,257,612)
Net non-operating activity	301,083	-	-	(979,008)	11,493	(4,099,760)	-	(4,766,192)
Excess of revenues (under) over expenses	\$ 3,923,502	\$ (2,715,288)	\$ (283,790)	\$ (1,024,934)	\$ 2,501	\$ (4,099,760)	\$ -	\$ (4,197,769)

Kennedy Krieger Institute, Inc. and Affiliates
Combining Statement of Changes in Net Assets
Year Ended June 30, 2020

	Kennedy Krieger Children's Hospital, Inc	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	Kennedy Krieger Education & Community Services, Inc.	Kennedy Krieger Foundation Inc.	PACT: Helping Children with Special Needs, Inc.	Madison Street Properties Inc.	Consolidating Eliminations	Consolidated Totals
Net assets without donor restrictions:								
Excess of revenue over (under) expenses	\$ 3,923,502	\$ (2,715,288)	\$ (283,790)	\$ (1,024,934)	\$ 2,501	\$ (4,099,760)	\$ -	\$ (4,197,769)
Net assets released from restrictions used for property and equipment						1,041,569		1,041,569
Change in funded status of defined benefit plan	(4,846,274)							(4,846,274)
Increase (decrease) in net assets without donor restrictions	(922,772)	(2,715,288)	(283,790)	(1,024,934)	2,501	(3,058,191)		(8,002,474)
Net assets without donor restrictions, beginning of year	33,327,480	(16,885,315)	13,045,007	57,397,149	418,427	14,472,687	(185,000)	101,590,435
Net assets without donor restrictions, end of year	32,404,708	(19,600,603)	12,761,217	56,372,215	420,928	11,414,496	(185,000)	93,587,961
Net assets with donor restrictions:								
Contributions with donor restrictions	759,775	10,319,943	928,795	(1,442,891)	399,859			10,965,481
Net assets released from restrictions used for:								
Operating activities	(1,049,351)	(1,725,641)	(809,044)	(3,063,192)	(78,224)			(6,725,452)
Purchases of property and equipment		(500,000)	(399,419)	(142,150)				(1,041,569)
Increase (decrease) in net assets with donor restrictions	(289,576)	8,094,302	(279,668)	(4,648,233)	321,635			3,198,460
Net assets with donor restrictions, beginning of year	3,415,475	2,826,442	1,222,718	16,062,928	772,635			24,300,198
Net assets with donor restrictions, end of year	3,125,899	10,920,744	943,050	11,414,695	1,094,270	-	-	27,498,658
Increase (decrease) in total net assets	(1,212,348)	5,379,014	(563,458)	(5,673,167)	324,136	(3,058,191)		(4,804,014)
Total net assets, beginning of year	36,742,955	(14,058,873)	14,267,725	73,460,077	1,191,062	14,472,687	(185,000)	125,890,633
Total net assets, end of year	\$35,530,607	(\$8,679,859)	\$13,704,267	\$67,786,910	\$1,515,198	\$11,414,496	(\$185,000)	\$121,086,619

Kennedy Krieger Institute, Inc. and Affiliates
Notes to Supplemental Consolidating Financial Statements
for the year ended June 30, 2020

1. Basis of Presentation and Accounting

The consolidating supplemental schedules have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

The Supplemental Consolidating Financial Statements presented on pages 37-39 were derived from and relate directly to the underlying accounting and other records used to prepare the consolidated financial statements. The consolidating information is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial positions and changes in net assets of the individual companies within the Institute and are not a required part of the consolidated financial statements. The individual affiliates within the Institute as presented within the supplemental consolidating financial statements are disclosed within Note 1 to the consolidated financial statements.

**Schedule of Expenditures of Federal Awards
and
Notes to Schedule of Expenditures of Federal Awards**

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
<u>Research and Development Cluster- Direct Awards</u>						
<u>Department of Health and Human Services</u>						
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-01	-	12,369	12,369
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-02	115,039		115,039
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-02	81,825		81,825
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-02	-	38,000	38,000
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-02	-	24,000	24,000
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-02	-	20,057	20,057
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-03	210,656		210,656
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-03	73,202		73,202
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-03	-	25,153	25,153
Maternal Child Health Careers/Research Initiatives-Undergrad	R	93.456	U50 MN000004-03	-	14,618	14,618
<i>Subtotal Centers for Disease Control & Prevention 93.456</i>						614,919
<u>National Heart Lung, and Blood Institute</u>						
MRI-based Quantitative Brain Perfusion Mapping for Sickle Cell Disease	R	93.839	K 25 HL121192-05	61,810		61,810
Clinical and Neuroimaging Phenotypes of Neurological Disorders In Pediatric Sickle Cell Disease	R	93.839	K 23 HL133455-01A	11,505		11,505
Clinical and Neuroimaging Phenotypes of Neurological Disorders In Pediatric Sickle Cell Disease	R	93.839	K 23 HL133455-02A	17,967		17,967
Clinical and Neuroimaging Phenotypes of Neurological Disorders In Pediatric Sickle Cell Disease	R	93.839	K 23 HL133455-03A	138,017		138,017
MRI-based Quantitative Brain Oximetry for Sickle Cell Disease	R	93.839	K25 HL145129-01	156,461	6,101	162,562
MRI-based Quantitative Brain Oximetry for Sickle Cell Disease	R	93.839	K25 HL145129-02	66,533		66,533
<i>Subtotal National Heart Lung and Blood Institute 93.839</i>						458,393
Non-Contrast-Enhanced Velocity-Selective MR Angiography	R	93.837	R01HL138182-02	26,311		26,311
Non-Contrast-Enhanced Velocity-Selective MR Angiography	R	93.837	R01HL138182-03	266,376		266,376
Velocity-Selective Arterial Spin Labeling based Perfusion Mapping for Cerebrovascular Diseases	R	93.837	R01HL144751-01	177,356		177,356
<i>Subtotal National Heart Lung and Blood Institute 93.837</i>						470,043
<u>National Institute of Biomedical Imaging and Bioengineering</u>						
Resources for Quantitative Functional MRI	R	93.286	P41 RR15241-18	172,009		172,009
Resources for Quantitative Functional MRI	R	93.286	P41 RR15241-18 Miller sub	-	42,750	42,750
Resources for Quantitative Functional MRI	R	93.286	P41 RR15241-18 Caffo sub	-	7,040	7,040
Resources for Quantitative Functional MRI	R	93.286	P41 RR15241-19	896,068	17,480	913,548
Resources for Quantitative Functional MRI	R	93.286	P41 RR15241-19 Miller sub	-	180,972	180,972
Resources for Quantitative Functional MRI	R	93.286	P41 RR15241-19 Caffo sub	-	95,403	95,403
Resources for Quantitative Functional MRI	R	93.286	P41 RR15241-20	96		96
Novel Approaches for CEST Labeling, Detection, Quantification and Translation	R	93.286	5 R01 EB015032-07	5,096		5,096
Novel Approaches for CEST Labeling, Detection, Quantification and Translation	R	93.286	5 R01 EB015032-08	340,041		340,041
Development and Translation of D-Glucose as a Diagnostic Agent for MRI	R	93.286	R01EB019934-04	196,942		196,942
Development and Translation of D-Glucose as a Diagnostic Agent for MRI	R	93.286	R01EB019934-05	420,264	19,647	439,911

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Presurgical Functional MRI in Patients w/ Large Susceptibility Artifacts	R	93.286	R21EB023538-02	46,524		46,524
Role of Peripheral and Brain Iron in the Development of Attention	R	93.286	R03EB023359-01A1	3,916		3,916
Development and Translation of D-Glucose as an MRI Contrast Agent for MS	R	93.286	1K99EB026312-01A1	2,374		2,374
Development and Translation of D-Glucose as an MRI Contrast Agent for MS	R	93.286	1K99EB026312-02	56,919		56,919
Sensitivity Enhanced MRI Imaging of Receptor Binding in Breast Cancer	R	93.286	R21EB025295-01A1	97,688		97,688
Sensitivity Enhanced MRI Imaging of Receptor Binding in Breast Cancer	R	93.286	R21EB025295-02A	129,282		129,282
Sensitivity Enhanced MRI Imaging of Receptor Binding in Breast Cancer	R	93.286	R21EB025295-03A	17,950		17,950
<i>Subtotal National Institute of Biomedical Imaging and Bioengineering 93.286</i>						<u>2,748,459</u>
National Institute of Child Health and Human Development						
Resident Training in Brain Injury Rehab	R	93.865	5T32HD007414-25	71,063		71,063
Resident Training in Brain Injury Rehab	R	93.865	5T32HD007414-25	190,509		190,509
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865	R01 HD40289-15A	35,710		35,710
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865	R01 HD40289-16A	196,349		196,349
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865	R01 HD40289-16A	-	13,137	13,137
Mechanism & Rehabilitation of Cerebella Ataxia	R	93.865	R01 HD40289-17A	51,680		51,680
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-12	-	70	70
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-12 CELNIK SUB	-	2	2
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-13	51,983		51,983
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-13 CELNIK SUB	(5,123)	8,666	3,543
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-13 KRAKA SUB	-	3,283	3,283
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-13 ZIPUNN SUB	-	6,014	6,014
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-14	321,946		321,946
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-14 CELNIK SUB	5,123	12,112	17,235
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-14 ZIPUNN SUB	-	25,548	25,548
Human Locomotors Plasticity in Health and Disease	R	93.865	R37 NS090610-15	20,715		20,715
Delineating Subtypes of Self-Injurious Behavior Maintained by Automatic	R	93.865	R01 HD076653-06	207,747	12,193	219,940
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-03	(38)		(38)
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04	(148)		(148)
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04	(206)		(206)
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04	(600)		(600)
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-04	(480)		(480)
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06	234,975		234,975
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06	339,696	18,918	358,614
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06	119,344	24,848	144,192
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06	30,009		30,009
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06	160,086	9,756	169,842
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06	121,199		121,199
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-06	138,697		138,697
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-07	5,642		5,642
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-07	81		81
Intellectual and Developmental Disabilities Research Centers 2013	R	93.865	U54 HD079123-07	1,198		1,198

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Mechanisms Regulating KCC@ Hypofunction	R	93.865	R01 HD090884-01	(587)		(587)
Mechanisms Regulating KCC@ Hypofunction	R	93.865	R01 HD090884-02	18,828	13,446	32,274
Mechanisms Regulating KCC@ Hypofunction	R	93.865	R01 HD090884-03	334,359		334,359
Mechanisms Regulating KCC@ Hypofunction	R	93.865	R01 HD090884-04	296		296
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-01	143,012		143,012
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-01- TEKES SUB	-	1,040	1,040
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-02	410,636		410,636
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-02-CAFFO SUB	-	14,554	14,554
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-02-TEKES SUB	-	20,801	20,801
Subtle Motor Functioning and Functional Connectivity in Youth After Mild TBI	R	93.865	R01HD090266-03	148,264		148,264
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865	R01HD097619-01A1	192,134		192,134
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865	R01HD097619-01A1 CELNIK SUB	-	8,758	8,758
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865	R01HD097619-01A1JHU SUB	-	3,346	3,346
Subjective Valuation of Ohysical Effort in Health and Disease	R	93.865	R01HD097619-01A1	33		33
Identifying Precursors to Severe Problem Behavior	R	93.865	R03HD096180-01A1	55,089		55,089
<i>Subtotal National Institute of Child Health and Human Development 93.865</i>						<u>3,795,713</u>

National Institute of Mental Health

Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-11SA1	3		3
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-11SA1	13,830		13,830
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-12A1	127,410		127,410
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1	252,066		252,066
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1-SUPP	18,781	9,767	28,548
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 CAFFO SUB	-	856	856
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 GIEDD SUB	-	539	539
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 COHEN SUB	-	17,046	17,046
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 COHEN SUB	368,766		368,766
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 COHEN SUB	-	36,558	36,558
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 COHEN SUB	-	7,150	7,150
Adolescent Changes in Brain and Behavior in Boys and Girls with ADHD	R	93.242	R01MH085328-13A1 COHEN SUB	-	6,077	6,077
Delay Discounting in children with ADHD: Neuroimaging	R	93.242	K23 MH101322-02	332		332
Delay Discounting in children with ADHD: Neuroimaging	R	93.242	K23 MH101322-04	20,139		20,139
Delay Discounting in children with ADHD: Neuroimaging	R	93.242	K23 MH101322-05	(6,611)		(6,611)
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-02	(8)		(8)
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-03	(11)		(11)
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-04	145,725		145,725
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-04-SUPL	4,848		4,848
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-04-LANDMEAD SUE	(14,789)	1,270	(13,519)
Role of Somatic Mosaicism in Autism, Schizophrenia and Bipolar Disorder Brain	R	93.242	U01MH106884-05-SUPL	143,364		143,364
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-01	36,818		36,818
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-01-PHILIPS SUB	(479)		(479)
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-02	45,674		45,674

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-02 UWash Sub	12,956		12,956
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-02-PHILIPS SUB	11,423		11,423
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-03	107,421		107,421
Virtual Brain Electrode (VIBE) for Imaging Neuronal Activity	R	93.242	R24MH109085-03 UWash Sub	(64,434)		(64,434)
Visual-Motor Development in Infants at High Risk for Autism	R	93.242	K01MH109766-02	20,934		20,934
Visual-Motor Development in Infants at High Risk for Autism	R	93.242	K01MH109766-04	96,418		96,418
Visual-Motor Development in Infants at High Risk for Autism	R	93.242	K01MH109766-05	21,698		21,698
Defining the Sluggish Cognitive Tempo Phenotype	R	93.242	R03 MH111965-01A	40		40
Defining the Sluggish Cognitive Tempo Phenotype	R	93.242	R03 MH111965-02A	10,067		10,067
A Novel Framework for Impaired Imitation in ASD	R	93.242	R01 MH113652-01A	103,925		103,925
A Novel Framework for Impaired Imitation in ASD	R	93.242	R01 MH113652-01-SUB	(37,302)		(37,302)
A Novel Framework for Impaired Imitation in ASD	R	93.242	R01 MH113652-02A	(25,587)	3,786	(21,801)
A Novel Framework for Impaired Imitation in ASD	R	93.242	R01 MH113652-03A	394,267	37,107	431,374
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242	R56 MG113627-01A1	101,630		101,630
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242	R56 MG113627-01A1 CELNIK SUB	-	3,400	3,400
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242	R56 MG113627-01A1 FRYDMAN SU	-	18,494	18,494
Genomic Basis of Pediatric Bipolar Disorder	R	93.242	R36 MH118005-01	13,698		13,698
Behavioral and Neural Representations of Subjective Effort Cost	R	93.242	R01MH119086-01A1	209,070	8,758	217,828
Examinatin of Developmental Trajectories of Cognitive, Motor, & Emotional Control	R	93.242	R03MH119457-01A1	23,588		23,588
Subtotal National Institute of Mental Health 93.242						2,306,477
National Institute of Neurological Disorders and Stroke						
Magnetic Resonance Imaging and Apectroscopy	R	93.853	K23NS091379-03	5,019		5,019
Magnetic Resonance Imaging and Apectroscopy	R	93.853	K23NS091379-04	14,762		14,762
Magnetic Resonance Imaging and Apectroscopy	R	93.853	K23NS091379-05	84,525		84,525
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-01	18		18
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-02	(19,157)		(19,157)
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-03	8,692		8,692
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-04	8,220	3,314	11,534
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-04 ZHU SUB	-	12,836	12,836
Methyl-CpG-dependent transcription factor function in human glioma	R	93-853	R01NS091165-05	234,329	4,638	238,967
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-01	(8,654)		(8,654)
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-01 EDDEN SUB	(5,322)		(5,322)
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-02	68,426		68,426
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-02 CAFFO SUB	(2,446)		(2,446)
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-02 EDDEN SUB	5,322		5,322
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-03	61,629		61,629
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-03 CAFFO SUB	2,979		2,979
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-03 EDDEN SUB	6,290		6,290
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-03 CINN SUB	42,779		42,779
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-04	158,530		158,530
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-04 CAFFO SUB	(2,745)	10,974	8,229

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-04 EDDEN SUB	(6,290)	42,623	36,333
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-04 CINN SUB	(42,779)	214,865	172,086
GABAergic Sensorimotor Dysfunction in Tourette Syndrome	R	93-853	R01NS096207-05	23,584		23,584
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-03	38,612		38,612
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-04	221,385		221,385
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-04 SUB	-	36,688	36,688
Targeted Therapies for Neonatal White Matter Injury	R	93-853	R01NS097511-05	51,279		51,279
Child Neurologist Career Development Program	R	93-853	K12NS098482-01	3,010		3,010
Child Neurologist Career Development Program	R	93-853	K12NS098482-01 BAYLOR SUB	-	(12,434)	(12,434)
Child Neurologist Career Development Program	R	93-853	K12NS098482-01 JHU SUB	-	37,544	37,544
Child Neurologist Career Development Program	R	93-853	K12NS098482-01 UCAL SUB	(138,080)	17,086	(120,994)
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 COLO SUB	-	440	440
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 IOWA SUB	-	10,085	10,085
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 BAYLOR SUB	-	25,852	25,852
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 JHU SUB	-	126,508	126,508
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 UCAL SUB	20,940	111,645	132,585
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 DUKE SUB	-	15,471	15,471
Child Neurologist Career Development Program	R	93-853	K12NS098482-02 BOSTON SUB	-	162,732	162,732
Child Neurologist Career Development Program	R	93-853	K12NS098482-03	3,279		3,279
Child Neurologist Career Development Program	R	93-853	K12NS098482-03 COLO SUB	-	19,353	19,353
Child Neurologist Career Development Program	R	93-853	K12NS098482-03 CORNELL SUB	-	14,956	14,956
Child Neurologist Career Development Program	R	93-853	K12NS098482-03 IOWA SUB	-	95,135	95,135
Child Neurologist Career Development Program	R	93-853	K12NS098482-03 CH HOSP SUB	-	51,036	51,036
Child Neurologist Career Development Program	R	93-853	K12NS098482-03 JHU SUB	-	142,214	142,214
Child Neurologist Career Development Program	R	93-853	K12NS098482-03 UCAL SUB	117,140	38,801	155,941
Child Neurologist Career Development Program	R	93-853	K12NS098482-03 SEATTLE SUB	-	38,895	38,895
Child Neurologist Career Development Program	R	93-853	K12NS098482-03-STANFORD SUB	-	32,349	32,349
Child Neurologist Career Development Program	R	93-853	K12NS098482-03-WASH SUB	-	44,852	44,852
Child Neurologist Career Development Program	R	93-853	K12NS098482-03	-	79,971	79,971
Child Neurologist Career Development Program	R	93-853	K12NS098482-04	107,082		107,082
Chromatin Modifications in GBM-Propagating Cells	R	93-853	R01NS096754-01A	(1,710)		(1,710)
Chromatin Modifications in GBM-Propagating Cells	R	93-853	R01NS096754-02A	(68,293)		(68,293)
Chromatin Modifications in GBM-Propagating Cells	R	93-853	R01NS096754-03A	201,689		201,689
Chromatin Modifications in GBM-Propagating Cells	R	93-853	R01NS096754-03A JHU SUB	-	51,548	51,548
Chromatin Modifications in GBM-Propagating Cells	R	93-853	R01NS096754-04A	54,561		54,561
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853	R01NS099460-01	(24,290)		(24,290)
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853	R01NS099460-02	125,576		125,576
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853	R01NS099460-03	271,409		271,409
Targeting Hyaluronan-Mediated Motility Receptor in Glioblastoma Stem Cells	R	93.853	R01NS099460-04	103		103
Targeting TAZ-driven Oncogenic Signaling in Medulloblastoma	R	93.853	R21NS106407-01	19,983		19,983
Targeting TAZ-driven Oncogenic Signaling in Medulloblastoma	R	93.853	R21NS106407-01	1	(1,388)	(1,387)
Targeting TAZ-driven Oncogenic Signaling in Medulloblastoma	R	93.853	R21NS106407-02	97,327		97,327
Defining the Ischemic Penumbra by pH Mapping in Acute Ischemia	R	93.853	R03NS109664-01	16,027	4,990	21,017

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Defining the Ischemic Penumbra by pH Mapping in Acute Ischemia	R	93.853	R03NS109664-01	55,892	15,174	71,066
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-01	(28,167)		(28,167)
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-01 JHU SUB	49,991		49,991
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-02	377,855		377,855
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-02 SUPP	75,407	76,708	152,115
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-02 JHU SUB	21,911	123,465	145,376
Imaging Small Blood and Lymphahtic Vessel Abnormalities	R	93.853	R01NS108452-03	32,600		32,600
Cerebrovascular Abnormalities in Huntingtons Disease	R	93.853	R21NS104480-01A1	24,959		24,959
Cerebrovascular Abnormalities in Huntingtons Disease	R	93.853	R21NS104480-01A1 JHU SUB	-	11,399	11,399
Cerebrovascular Abnormalities in Huntingtons Disease	R	93.853	R21NS104480-02A1	86,043	43,031	129,074
Cerebrovascular Abnormalities in Huntingtons Disease	R	93.853	R21NS104480-02A1 JHU SUB	43,031	2,175	45,206
Paracrine Angiotensin II Signaling Promotes Medulloblastoma	R	93.853	R21NS101400-01A1	73,752		73,752
Paracrine Angiotensin II Signaling Promotes Medulloblastoma	R	93.853	R21NS101400-02A1	113,754		113,754
Cortical Functional Connectivity as an Early Biomarker of Recovery in SCI	R	93.853	R21NS104644-01A1	11,477		11,477
Cortical Functional Connectivity as an Early Biomarker of Recovery in SCI	R	93.853	R21NS104644-02	132,538		132,538
Tet2 Regulation and Function in Glioma Cell Phenotype Reprogramming	R	93.853	R01NS110087-01A1	194,040		194,040
Tet2 Regulation and Function in Glioma Cell Phenotype Reprogramming	R	93.853	R01NS110087-01A1	8,306		8,306
Subtotal National Institute of Neurological Disorders and Stroke 93.853						4,733,665
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394	R01CA211087-01A	(68,494)		(68,494)
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394	R01CA211087-02A	29,257		29,257
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394	R01CA211087-03A	230,734	14,765	245,499
Noninvasive Prediction of Tumor Response to Gemcitabine using MRI	R	93.394	R01CA211087-04A	135,481		135,481
Subtotal National Cancer Institute 93.394						341,742
Preventive Dyadic Intervention to Enhance Communication	R	93.173	R21DC015846-02A1	9,832		9,832
Subtotal National Institute on Deafness & Other Communication 93.173						9,832
National Institute on Aging						
Leveraging energetics to Improve Gait Rehabilitation after Stroke	R	93.866	R21 AG059184-01A1	69,243	12,481	81,724
Leveraging energetics to Improve Gait Rehabilitation after Stroke	R	93.866	R21 AG059184-02A1	125,002	27,997	152,999
Impaired Cerebral Glucose Uptake in the Brain as an MRI marker for Alzheimer's Disease	R	93.866	R21 AG065794-01	56,079	11,860	67,939
Contributions of Local Cerebral Iron to Cognitive Decline during Aging and Preclinical Alzheimer's Disease	R	93.866	R03 AG065527	8,301	1,331	9,632
Subtotal National Institute on Aging 93.866						312,293
Office of the Director - National Institutes of Health						
Magnetic Particle Imaging Scanner	R	93.351	S10OD026740-01	420,000		420,000
Subtotal Office of the Director 93.351						420,000
National Institute of Diabetes and Digestive and Kidney Diseases						
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847	R01DK121847-01A1	200	2,738	2,938
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847	R01DK121847-01A1	-	1,458	1,458

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Developing MRI Contrast Agents to Detect Progression in Renal Disease	R	93.847	R01DK121847-01A1	-	1,458	1,458
<i>Subtotal National Institute of Diabetes and Digestive and Kidney Disease</i>						5,854
Total Department of Health and Human Services						16,217,391
<u>The Health Resources and Services Administration</u>						
MCH RESEARCH	R	93.110	T16MC29832-03	210		210
MCH RESEARCH	R	93.110	T16MC29832-04	163,213		163,213
MCH RESEARCH	R	93.110	T16MC29832-05	18,122		18,122
<i>Subtotal HRSA CFDA 93.110</i>						181,545
Telehealth Network Grant Program	R	93.211	H2ARH30299-02	1,519		1,519
Telehealth Network Grant Program	R	93.211	H2ARH30299-03	23,661		23,661
Telehealth Network Grant Program	R	93.211	H2ARH30299-04	258,875		258,875
						284,055
Total Health Resources and Services Administration						465,600
<u>US Army Medical Research</u>						
Neurovascular Changes Associated with Olfactory Deficits in Early Parkinson's Disease	R	12.420	W81XWH017-PRP-FIA	150,035		150,035
Alzheimers Research Program	R	12.420	W81XWH1810797	113,406	39,324	152,730
<i>Subtotal US Army Medical Research CFDA 12.420</i>						302,765
Total Research and Development - Direct Awards						16,985,757
<u>Research and Development Cluster- Pass Through Awards</u>						
<u>Johns Hopkins University</u>						
Neurobehavioral Correlates of Frustration in Children with ADHD	R	93.242	2002610904	6,641		6,641
Neurobehavioral Correlates of Frustration in Children with ADHD	R	93.242	2002610904	6,537		6,537
Neurobehavioral Correlates of Frustration in Children with ADHD	R	93.242	2002610904	12,887		12,887
Neurobehavioral Correlates of Frustration in Children with ADHD	R	93.242	2002610904	(8,389)		(8,389)
Neurobehavioral Correlates of Frustration in Children with ADHD	R	93.242	2002610904	31,346		31,346
Somatossensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242	2003046760	(18,045)		(18,045)
Somatossensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242	2003046760	(2,274)		(2,274)
Somatossensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242	2003046760	33,879		33,879

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Somatosensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242	2003046760	245,440		245,440
Somatosensory Inhibitory Dysfunction in Autism Spectrum Disorder	R	93.242	2003046760	84,422		84,422
Investigation of Cerebellar Involvement in Cognitive Function	R	93.242	2002590758	12,532		12,532
Thalamic Connectivity in Recent Onset Schizophrenia	R	93.242	2002832607	23,511		23,511
Thalamic Connectivity in Recent Onset Schizophrenia	R	93.242	2002832607	806		806
Neuroimaging Epigenetics of Prospective Postpartum Depression	R	93.242	2002412818	1,333		1,333
Multimodal Investigation of Inhibitory Dysfunction in Autism	R	93.242	2003902559	81		81
Multimodal Investigation of Inhibitory Dysfunction in Autism	R	93.242	2003902559	13,013		13,013
Feasibility, Acceptability, and Preliminary Efficacy of Text4Father for Improving Infant & Family Health	R	93.242	2004623345	4,675		4,675
Gene-Environment Interactions for Cortical Development and Schizophrenia	R	93.242	2003126169	23,498		23,498
Subtotal JHU CFDA 93.242						471,894
HIV-Related Neuroplasticity and Attention to Reward as Predictors	R	93.279	2003097253	(1,600)		(1,600)
HIV-Related Neuroplasticity and Attention to Reward as Predictors	R	93.279	2003097253	18,277		18,277
Combined mGluR5 PET and fMRI Imaging of Sex Differences during Cocaine Withdrawal	R	93.279	2003527176	10,132		10,132
Developing plans for a Baltimore site if the HEALthy BCD study	R	93.279	2004576594	11,130		11,130
Subtotal JHU CFDA 93.279						37,940
High-Specificity Imaging Agents for Aggressive Prostate Cancer	R	93.394	2003179660	6,136		6,136
High-Specificity Imaging Agents for Aggressive Prostate Cancer	R	93.394	2003179660	9,570		9,570
Amide Proton Transfer MRI of Brain Tumors at 3T	R	93.394	2004159420	2,133		2,133
Highly Accelerated Chemical Exchange Saturation Transfer MRI Using Compressed Sensing	R	93.394	2004334298	9,712		9,712
A Wireless Multi-Function Microscope for Lifetime Imaging of the Brain Tumor Vasculome	R	93.394	2004637973	23,393		23,393
Subtotal JHU CFDA 93.394						50,945
Centers for Autism & Developmental Disabilities Research	R	93.073	2001438612	16		16
Centers for Autism & Developmental Disabilities Research	R	93.073	2001438612	198,275		198,275
Subtotal JHU CFDA 93.703						198,291
Excitotoxicity in Circulatory Arrest-Brain Injury	R	93.837	2002405038-2002405090	(38)		(38)
Excitotoxicity in Circulatory Arrest-Brain Injury	R	93.837	2002405038-2002405090	(18)		(18)
Computational Assessment of Galectin-3 Significance in Heart Failure	R	93.837	2003534038	157,538		157,538
Subtotal JHU CFDA 93.837						157,482
Functional & Molecular Properties of PAX7	R	93.846	2003341654	3,605		3,605
Functional & Molecular Properties of PAX7	R	93.846	2003341654	41,923		41,923
Functional & Molecular Properties of PAX7	R	93.846	2003341654	7,130		7,130
Subtotal JHU CFDA 93.846						52,657

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Development of MRI Microvascular Biomarkers	R	93.853	2003335096	(28,469)		(28,469)
Imaging Neurodegeneration in MS	R	93.853	2003795776	79,235		79,235
Development of Dendrimer N Acetylcysteine for the Treatment of Neonatal Brain Injury	R	93.853	2004023957	8,139		8,139
Development of Dendrimer N Acetylcysteine for the Treatment of Neonatal Brain Injury	R	93.853	2004023957	4,999		4,999
Development of MRI Microvascular Biomarkers in Cognitive Impairment and Dementia	R	93.853	2003986087	15,367		15,367
Development of MRI Microvascular Biomarkers in Cognitive Impairment and Dementia	R	93.853	2003986087	105,453		105,453
Lymphocyte CpG Methylation Changes and Brain Pathology in Restless Leg Syndrome	R	93.853	2004063802	34,801		34,801
Lymphocyte CpG Methylation Changes and Brain Pathology in Restless Leg Syndrome	R	93.853	2004063802	2,160		2,160
Targeted Therapies for Rett Syndrome	R	93.853	2004344161	52,660		52,660
MOVE - Modeling of Fast Movement for Enhancement via Neuroprosthetics	R	93.853	2004347342	14,806		14,806
MOVE - Modeling of Fast Movement for Enhancement via Neuroprosthetics	R	93.853	2004347342	4,634		4,634
Development of Novel Functional Markers for TBI Using Molecular MRI	R	93.853	2004487313	19,392		19,392
Subtotal JHU CFDA 93.853						313,177
Adult Biomarkers in Neonatal Brain Injury	R	93.865	2003671299	11,712		11,712
Adult Biomarkers in Neonatal Brain Injury	R	93.865	2003671299	69,495		69,495
CSA as a Preventable Public Health Problem	R	93.865	2004209564	11,816		11,816
MRI Biosensors and Complementary DRUG Nonoccarriers for Effective Image Guided Drug Delivery	R	93.865	2004411797	21,226		21,226
Subtotal JHU CFDA 93.865						114,249
Biomarkers of Cognitive Decline Among Normal Individual: the Biocard Cohort	R	93.866	2002373351	82,149		82,149
Alzheimers Research	R	93.866	2002582670	20,616		20,616
Alzheimers Research	R	93.866	2002582670	13,065		13,065
Longitudinal Molecular Imaging of Neuropathology	R	93.866	2003816131	10,763		10,763
Brain Oxygen Consumption as an MRI Biomarker	R	93.866	2003950256	9,990		9,990
Neural Network Connectivity of Financial Capacity in Mild Cognitive Impairment	R	93.866	2003527906	13,948		13,948
Neurometabolic Profil of Mild Cognitive Impairment Using Multiplexed Edited MRS	R	93.866	2004031612	30,979		30,979
Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers	R	93.866	2004149879	15,339		15,339
Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers	R	93.866	2004149879	9,314		9,314
Calibration or fMRI in Emotional Aging	R	93.866	2004190130	1,333		1,333
Early Onset AD Consortium - LEADS	R	93.866	2004394773	19,247		19,247
Contribution of Cerebral Iron Load to Elderly Individuals with High Risk for Alzheimers	R	93.866	2004407223	26,512		26,512
Phase II/III Trial for Slowing Progression in Mild Cognitive Impairment	R	93.866	2004141582	17,798		17,798
Subtotal JHU CFDA 93.866						271,052
Neurodegenerative and Neurodevelopmental Subcortical Shape Diff	R	93.286	2003386771	17,024		17,024
Neurodegenerative and Neurodevelopmental Subcortical Shape Diff	R	93.286	2003386771	24,997		24,997
Neurodegenerative and Neurodevelopmental Subcortical Shape Diff	R	93.286	2003386771	70,140		70,140

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Simultaneous Hadamard Editing of GABA and Glutathione	R	93.286	2003385023	6,545		6,545
Label-Free Imaging Research for Technical Innovations	R	93.286	2003464965	7,192		7,192
Resource for Molecular Imaging agents in Precision Medicine	R	93.286	2003638047	14,805		14,805
Resource for Molecular Imaging agents in Precision Medicine	R	93.286	2003638047	22,578		22,578
Resource for Molecular Imaging agents in Precision Medicine	R	93.286	2003638047	57,861		57,861
Universal Edited MRS at 3T	R	93.286	2003941240	59,956		59,956
Subtotal JHU CFDA 93.286						<u>281,098</u>
Hardening and Scaling Core Genomics Software	R	93.859	2003129512	3,338		3,338
Subtotal JHU CFDA 93.859						<u>3,338</u>
Investigating Air Pollution Effects on the Developing Brain and ASD	R	93.113	2003188501	(6)		(6)
Investigating Air Pollution Effects on the Developing Brain and ASD	R	93.113	2003188501	513		513
Investigating Air Pollution Effects on the Developing Brain and ASD	R	93.113	2003188501	670		670
Investigating Air Pollution Effects on the Developing Brain and ASD	R	93.113	2003188501	29,810		29,810
Subtotal JHU CFDA 93.113						<u>30,987</u>
Stress and Chronic Alcohol Interactions	R	93.273	2003325699	47,175		47,175
Subtotal JHU CFDA 93.273						<u>47,175</u>
JH - Center for Excellence in Regulatory Science and Innovation	R	93.103	2004253590	2,885		2,885
JH - Center for Excellence in Regulatory Science and Innovation	R	93.103	2004231016	37,802		37,802
Subtotal JHU CFDA 93.103						<u>40,687</u>
Discovering Network Structure in the Space of Group Level Functional Differences	R	47.RD	2004042235	38,887		38,887
Subtotal JHU CFDA 47.RD						<u>38,887</u>
Identifying Model-Based Motor Control Strategies	R	47.041	2004042235	20,486		20,486
Subtotal JHU CFDA 47.041						<u>20,486</u>
Evaluating the Metabolic Changes Associated with Exercise in MS	R	12.420	2003624821	6,027		6,027
Subtotal JHU CFDA 12.420						<u>6,027</u>
Gene Delivery Nanoparticles to Treat Glioblastoma	R	93.395	2004276542	167,532		167,532
Subtotal JHU CFDA 93.395						<u>167,532</u>
Johns Hopkins Institute for Clinical Translational Research	R	93.350	2004382572	159,600		159,600
Subtotal JHU CFDA 93.350						<u>159,600</u>
Johns Hopkins Institute for Clinical Translational Research	R	93.847	2004422191	9,313		9,313
Subtotal JHU CFDA 93.847						<u>9,313</u>

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Total Johns Hopkins University						2,472,816
University of California						
The Brain Vascular Matt Clinic Research	R	93.853	8397	22,969		22,969
The Brain Vascular Matt Clinic Research	R	93.853	8397	661		661
Subtotal University of California CFDA 93.853						23,630
University of Maryland, Baltimore						
Family Informed Trauma Treatment CTR-FITT	R	93.243	1701143	8,573		8,573
Family Informed Trauma Treatment CTR-FITT	R	93.243	1701143	32,147		32,147
Subtotal University of Maryland Baltimore CFDA 93.243						40,719
University of Maryland, Baltimore						
<i>National Center for Child Welfare Curriculum Development</i>	R	93.648	SR00005204	38,182		38,182
<i>National Center for Child Welfare Curriculum Development</i>	R	93.648	SR00005575	39,668		39,668
Subtotal University of Maryland Baltimore CFDA 93.648						77,850
Massachusetts General Hospital						
A CEST MRI Reporter Gene for Image Incolytic Virotherapy	R	93.394	228473	13,840		13,840
Subtotal Massachusetts General Hospital CFDA 93.394						13,840
University of Massachusetts						
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00463936/RFS2016036	(1,583)		(1,583)
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00764093/OSP2018146	(197)		(197)
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00764093/OSP2018146	18,750		18,750
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00764093/OSP2018146	1,756		1,756
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00764092/OSP2018147	(34,330)		(34,330)
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00764092/OSP2018147	136,998		136,998
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00764092/OSP2018147	3,512		3,512
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763694/OSP2018141	(398)		(398)
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763694/OSP2018141	18,750		18,750
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763694/OSP2018141	1,756		1,756
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763696/OSP2018145	(5,594)		(5,594)
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763696/OSP2018145	119,133		119,133
Biomarkers for Therapy of FSHD (U54)	R	93.865	WA00763696/OSP2018145	10,418		10,418
Subtotal University of Massachusetts CFDA 93.865						268,971
Henry Ford Health System						
Plasma Biomarkers of Cerebral Disease in X-Linked Adrenoleukodystrophy	R	93.853	U01AG051412-03	19,762		19,762
Subtotal Columbia University CFDA 93.866						19,762

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Baylor University						
Brittle Bone Disorders Consortium of the Rare Disease Clinical Network	R	93.846	U54AR068069	7,028		7,028
Brittle Bone Disorders Consortium of the Rare Disease Clinical Network	R	93.846	U54AR068069	65,644		65,644
<i>Subtotal Baylor University CFDA 93.846</i>						72,672
Drexel University						
An ASF Enriched Risk ECHO Cohort	R	93.310	UG30D023342	10,181		10,181
An ASF Enriched Risk ECHO Cohort	R	93.310	UG30D023342	96,930		96,930
<i>Subtotal Drexel University CFDA 93.310</i>						107,110
Columbia University						
Identification of Protective Factors for Cognitive Resilience in Adults with Downs Syndrome	R	93.866	4(GG013394-01)	34,476		34,476
<i>Subtotal Columbia University CFDA 93.866</i>						34,476
Leland Stanford Junior University						
Child Health and Human Development Extramural Research	R	93.865	61687287-47273	1,202		1,202
<i>Subtotal Leland Stanford Junior University CFDA 93.865</i>						1,202
Leland Stanford Junior University						
Effort of Vitamin D3 on Markers of Oxidative Stress in Boys with X Linked ALD	R	93.853	61849619-112050	4,404		4,404
<i>Subtotal Leland Stanford Junior University CFDA 93.853</i>						4,404
Partners Healthcare						
Oxidative Stress and Bipolar Disorder Trajectories	R	93.242	11614	6,930		6,930
<i>Subtotal Partners Healthcare CFDA 93.242</i>						6,930
University of Rochester						
Clinical Readiness to Solve Barriers to Drug Development in FSHD	R	93.853	417259/URFAO:GR510743	47,792		47,792
<i>Subtotal University of Rochester CFDA 93.853</i>						47,792
Case Western University						
Non-Contrast Enhanced Peripheral MR Angiography	R	93.837	RES514359	54,573		54,573
Non-Contrast Enhanced Peripheral MR Angiography	R	93.837	RES514359	73,304		73,304
<i>Subtotal Case Western University CFDA 93.837</i>						127,877
Children's Hospital Medical Center						
The Role of Executive Functions in Reading and Remediation	R	93.865	3100658971	31,203		31,203
<i>Subtotal Children's Hospital Medical Center CFDA 93.865</i>						31,203
Children's Hospital Medical Center						
Center for Dignity in Healthcare for People with Disabilities	R	93.631	309541	16,763		16,763
<i>Subtotal Children's Hospital Medical Center CFDA 93.631</i>						16,763

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Children's Hospital of Philadelphia						
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	3202030620	4,906		4,906
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	3202060620	19,143		19,143
The Global Leukodystrophy Initiative Clinical Trials Network	R	93.853	3202060620	98,559		98,559
<i>Subtotal Children's Hospital Medical Center CFDA 93.853</i>						<u>122,608</u>
North Carolina State University						
Social Adversities, Epigenetics and the Obesity Epidemic	R	93.307	2017-1593-01	75,551		75,551
Social Adversities, Epigenetics and the Obesity Epidemic	R	93.307	2017-1593-01	7,027		7,027
<i>Subtotal North Carolina State University CFDA 93.307</i>						<u>82,578</u>
United States Department of Education						
Efficacy Trial of Early Achievements Comp Intervention Preschoolers with Autism	R	84.324A	R 324 A160228	327,822		327,822
Efficacy Trial of Early Achievements Comp Intervention Preschoolers with Autism	R	84.324A	R 324 A160228	222,147		222,147
Development of an Intervention for Center-Based Early Childhood Education	R	84.324A	R 324 A180085	843		843
Development of an Intervention for Center-Based Early Childhood Education	R	84.324A	R 324 A180085	346,782		346,782
Development of an Intervention for Center-Based Early Childhood Education	R	84.324A	R 324 A180085	220		220
<i>Subtotal United States Department of Education CFDA 84.324A</i>						<u>897,814</u>
Total Research and Development Cluster - Pass Through Awards						<u><u>4,471,019</u></u>
Research and Development Cluster - Total Awards						<u><u>21,456,776</u></u>
<u>Other Programs - Direct Awards</u>						
Department of Health and Human Services						
Children's Hospital Graduate Medical Education	H	93.255	338-002	399,627		399,627
<i>Subtotal DHHS CFDA 93.255</i>						<u>399,627</u>
Administration for Children and Families						
Developmental Disabilities	H	93.632	90DD0707/04	569,912		569,912
<i>Subtotal ADD CFDA 93.632</i>						<u>569,912</u>
Total Department of Health and Human Services						<u><u>969,539</u></u>

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
The Health Resources and Services Administration						
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	94,246		94,246
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	86,857		86,857
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	9,008		9,008
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	23,592		23,592
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	14,158		14,158
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	79,864		79,864
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	14,240		14,240
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	44,681		44,681
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	3,122		3,122
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	76,944		76,944
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	3,098		3,098
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	12,938		12,938
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	20,063		20,063
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	13,488		13,488
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	16,278		16,278
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	3,734		3,734
MCH Training Program in Neurodevelopment Disabilities	H	93.110	2 T73 MC17245-11-00	320,085		320,085
<i>Subtotal MCH Training Program CFDA 93.110</i>						836,396
Total The Health Resources and Services Administration						836,396
Federal Communications Commission						
<i>COVID-19 - Telecommunications and Equipment</i>	H	32.006	0043	422,837		422,837
<i>Subtotal FCC CFDA 32.006</i>						422,837
Total Other Programs - Direct Awards						2,228,772
<u>Other Programs - Pass Through Awards</u>						
Governor's Office Of Crime Control & Prevention						
Underserved Victims	C	16.575	1299	(2,720)		(2,720)
Underserved Victims	C	16.575	1299	87,693		87,693
Underserved Victims	C	16.575	1299	228,840		228,840
<i>Subtotal Governor's Office CFDA 16.575</i>						313,814

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Maryland Department of Education						
<u>Child Nutrition Cluster</u>						
School Breakfast Program	C	10.553	9962	19,910		19,910
<i>Subtotal School Breakfast Program CFDA 10.553</i>						19,910
School Lunch Program	C	10.555	9962	(2,442)		(2,442)
School Lunch Program	C	10.555	9962	40,426		40,426
<i>Subtotal School Lunch Program CFDA 10.555</i>						37,984
Total Child Nutrition Cluster						57,894
<u>Special Education Cluster (IDEA)</u>						
Providing Technical Assistance to the Eastern Shore of Maryland	R	84.027	190323	-		0
Providing Technical Assistance to the Eastern Shore of Maryland	R	84.027	190323	111,014		111,014
Providing Technical Assistance to the Eastern Shore of Maryland	R	84.027	200829	199,999		199,999
Implementing Models of Best Practice to Improve Outcomes	R	84.027	190322	-		0
Implementing Models of Best Practice to Improve Outcomes	R	84.027	190322	82,122		82,122
<i>Subtotal Assitstance to the State for Education Students with Disabilities CFDA 84.027</i>						393,135
Pact: World Of Care Child Care Center	P	84.173	180782	11,275		11,275
Pact: World Of Care Child Care Center	P	84.173	180540	1,144		1,144
Pact: World Of Care Child Care Center	P	84.173		95,655		95,655
Pact: World Of Care Child Care Center	P	84.173	190384	11,408		11,408
Pact: Helping Children w/Special Needs Therapeutic Nursery -YMCA	P	84.173	190604	10,291		10,291
Pact: Helping Children w/Special Needs Therapeutic Nursery -YMCA	P	84.173	190604	113,771		113,771
<i>Subtotal PACT CFDA 84.173</i>						243,544
Total Special Education Cluster (IDEA)						636,679
Preschool Development	C	84.419	170362	10		10
Preschool Development	C	84.419	200630	197,884		197,884
<i>Subtotal MSDE CFDA 84.419</i>						197,894

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Project 4C	C	93.434	191621	73,497		73,497
<i>Subtotal MSDE CFDA 93.434</i>						73,497
<i>Infants and Toddlers with Disabilities</i>	C	84.181	191712	10,920		10,920
<i>Subtotal MSDE CFDA 84.181</i>						10,920
Total Maryland Department of Education						918,989
Maryland Developmental Disabilities Council						
Enhancing Advocacy & Public Policy Work Project	H	93.630	19-QA-01	46,068		46,068
Enhancing Advocacy & Public Policy Work Project	H	93.630	20-QA-01	73,607		73,607
Nurse Consultation and Coaching Demonstration Project	H	93.630	19-CC-01	75,445		75,445
<i>Subtotal Maryland Developmental Disabilities Council CFDA 93.630</i>						195,121
Maryland Department of Health and Mental Hygiene						
Genetics Laboratory	H	93.994	PHPA-G2084	38,320		38,320
Within My World	P	93.994	FH795CSN/PHPA-G-1165	400,000		400,000
Enhancing Child Care For Children	C	93.994	MR554 MFC	1,515		1,515
Enhancing Child Care For Children	C	93.994	MR554 MFC	353,684		353,684
Project STIR	C	93.994	DD964 ISS	89,775		89,775
Project STIR	C	93.994	DD964 ISS	91,044		91,044
<i>Subtotal DHMH CFDA 93.994</i>						974,337
Total Maryland Department of Health and Mental Hygiene						1,169,458
Maryland Family Network						
<u>Head Start Cluster</u>						
Southeast Baltimore EHS	C	93.600	362	3,981		3,981
Southeast Baltimore EHS	C	93.600	362	11,322		11,322
Maryland Family Network	P	93.600	3034	60,643		60,643
Maryland Family Network	P	93.600	3034	13,884		13,884
Maryland Family Network	P	93.600	3034	240,257		240,257
Early Head Start Center	C	93.600	650	(167)		(167)
Early Head Start Center	C	93.600	650	199,302		199,302

The accompanying notes are an integral part of this schedule

KENNEDY KRIEGER INSTITUTE, INC. AND SUBSIDIARIES
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
For the Fiscal Year Ended June 30, 2020

Federal Grantor/Pass-Through Grantor/Program or Cluster Title	Entity	Federal CFDA Number	Award/Pass Through Entity Identification Number	Recipient Expenditures	Subrecipient Expenditures	Total Federal Expenditures
Early Head Start Center	C	93.600	650	537,319		537,319
Early Head Start Center	C	93.600	650	(7)		(7)
<i>Subtotal Maryland Family Network CFDA 93.600</i>						<u>1,066,534</u>
Total Head Start Cluster						<u>1,066,534</u>
Baltimore Mental Health Systems						
Therapeutic Nursery	P	93.RD	POS#40	152,000		<u>152,000</u>
<i>Subtotal Baltimore Mental Health Systems CFDA 93.RD</i>						<u>152,000</u>
Baltimore City						
Baltimore City Infants & Toddlers Program	P	84.181A	CO#38176	46,124		46,124
Baltimore City Infants & Toddlers Program	P	84.181A	CO#38177	58,419		58,419
Baltimore City Infants & Toddlers Program	R	84.181A	CO#37753	42,685		<u>42,685</u>
<i>Subtotal Baltimore City CFDA 84.181A</i>						<u>147,228</u>
Baltimore City						
Family Support Services - Infants and Toddlers Program	P	93.RD	38278	80,361		<u>80,361</u>
<i>Subtotal Baltimore City CFDA 93.RD</i>						<u>80,361</u>
<i>Total Baltimore City</i>						<u>227,589</u>
Total Other Programs- Pass Through Awards						<u>3,906,278</u>
Total Other Programs- Total Awards						<u>6,135,050</u>
Total Expenditures of Federal Awards				24,921,994	2,669,834	<u><u>\$ 27,591,826</u></u>

The accompanying notes are an integral part of this schedule

Kennedy Krieger Institute, Inc. and Affiliates

Notes to Schedule of Expenditures of Federal Awards

Year Ended June 30, 2020

1. BASIS OF PRESENTATION

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") summarizes the expenditures of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute") under programs of the Federal Government for the year ended June 30, 2020. The information presented in the Schedule is presented on the accrual basis of accounting, which is in accordance with the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Expenditures for federal awards are determined using the cost principles set forth in the Uniform Guidance. Under these cost principles, certain types of expenditures are not allowable or are limited to reimbursement.

The accompanying Schedule includes the federal grant transactions of the Institute and includes Federal Awards made to the following corporate entities: Kennedy Krieger Children's Hospital, Inc., Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Kennedy Krieger Education & Community Services, Inc. and PACT: Helping Children with Special Needs, Inc. under programs of the federal government for the year ended June 30, 2020. These corporate entities are denoted on the Schedule as follows:

	Total Federal Expenditures	Passed to Subrecipients	
R:	\$ 21,892,596	\$ 2,669,834	<i>R – Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</i>
H:	2,462,212	-	<i>H – Kennedy Krieger Children's Hospital, Inc.</i>
C:	1,941,786	-	<i>C – Kennedy Krieger Education & Community Services, Inc.</i>
P:	<u>1,295,232</u>	<u>-</u>	<i>P – PACT: Helping Children with Special Needs, Inc.</i>
	<u>\$ 27,591,826</u>	<u>\$ 2,669,834</u>	

Because the Schedule presents only a selected portion of the operations of the Institute, it is not intended to and does not present the financial position, results of operations and non-operating activity, or cash flows of the Institute. Negative amounts reflect adjustments made to expenditures reported in prior years in the normal course of business.

For purposes of the Schedule, federal awards include all awards in the form of grants, contracts, and similar agreements entered into directly between the Institute and agencies and departments of the federal government, or non-federal pass-through entities. Federal CFDA and pass-through identification numbers are included when available.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Schedule reflects federal award program expenditures recognized on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. The Institute has not elected to use the 10% de minimis rate for indirect costs. Indirect costs are billed based upon negotiated and budgeted rates.

3. DEPARTMENT OF HEALTH AND HUMAN SERVICES PROVIDER RELIEF FUNDS

The Institute was the recipient of funding under CFDA # 93.498, Provider Relief Funds, and as required by the Addendum to the 2020 Compliance Supplement such expenditures have been excluded from the Schedule of Expenditures of Federal Awards for the year ending June 30, 2020.

4. COVID-19 Strategic National Stockpile Distribution (Unaudited)

During fiscal year 2020, The Institute received donated personal protective equipment (PPE) from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response strategic national stockpile related to the COVID-19 pandemic response efforts. The Institute received Masks, Gowns, Gloves and Face Shields with an estimated fair market value at the time of receipt of \$6.

Part II
Reports on Compliance and Internal Control



Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Directors of
Kennedy Krieger Institute, Inc. and Affiliates:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Kennedy Krieger Institute, Inc. and Affiliates (the "Institute"), which comprise the consolidated balance sheet as of June 30, 2020, and the related consolidated statements of operations and changes in net assets and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated October 15, 2020.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Institute's internal control over financial reporting ("internal control") as a basis for designing the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, we do not express an opinion on the effectiveness of the Institute's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Institute's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.



Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Baltimore, Maryland

October 15, 2020



**Report of Independent Auditors on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal
Control Over Compliance in Accordance with the Uniform Guidance**

To the Board of Directors of
Kennedy Krieger Institute, Inc. and Affiliates:

Report on Compliance for Each Major Federal Program

We have audited Kennedy Krieger Institute Inc. and Affiliates (the “Institute”) compliance with the types of compliance requirements described in *the OMB Compliance Supplement* that could have a direct and material effect on each of the Institute’s major federal programs for the year ended June 30, 2020. The Institute’s major federal programs are identified in the summary of auditors’ results section of the accompanying schedule of findings and questioned costs.

Management’s Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditors’ Responsibility

Our responsibility is to express an opinion on compliance for each of the Institute’s major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Institute’s compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the Institute’s compliance.

Opinion on Each Major Federal Program

In our opinion, the Institute complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2020.



Report on Internal Control Over Compliance

Management of the Institute is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Institute's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Institute's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

Baltimore, Maryland

June 4, 2021

Part III
Schedule of Findings and Questioned Costs

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Findings and Questioned Costs
Year Ended June 30, 2020

Section I – Summary of Auditor’s Results

Financial Statements

Type of auditor’s report issued on whether the financial statements audited were prepared in accordance with GAAP: Unmodified

Internal control over financial reporting:

Material weakness(es) identified? No

Significant deficiency(ies) identified? None Reported

Noncompliance material to financial statements noted? No

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified? No

Significant deficiency(ies) identified? None Reported

Type of auditor’s report issued on compliance for major federal programs: Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? No

Identification of major federal programs:

<u>Name of Federal Program or Cluster</u>	<u>CFDA Number(s)</u>
Research and Development Cluster	Various
Special Education Cluster (IDEA)	84.027

Dollar threshold used to distinguish between type A and type B programs: \$827,755

Auditee qualified as a low-risk auditee? Yes

Kennedy Krieger Institute, Inc. and Affiliates
Schedule of Findings and Questioned Costs
Year Ended June 30, 2020

Section II - Financial Statement Findings

There were no matters reported.

Section III - Federal Award Findings and Questioned Costs

There are no matters to report.

Summary Schedule of Prior Audit Findings

Kennedy Krieger Institute, Inc. and Affiliates
Summary Schedule of Prior Audit Findings
Year Ended June 30, 2020

Section II - Financial Statement Findings

No matters were reported that require an update in this report.

Section III - Federal Award Findings and Questioned Costs

No matters were reported that require an update in this report.